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1 SUMMARY 
Dendritic cells (DCs) play an important role in orchestrating both innate and 
adaptive immune responses. They are specialized in presenting antigens to T cells, 
which can be derived from self or foreign origin. DCs express a large variety of 
pattern recognition receptors (PRRs), which allow sensing and capturing of 
pathogenic invaders. During pathogen encounter DCs undergo a maturation 
process, which makes them potent stimulators of various T cell responses. In 
contrast, presentation of self-antigen induces tolerance in naive T cells. In this 
study, we used a lentiviral gene transfer system with DC-specific promoters to 
address various questions regarding DC biology in vivo. Thereby, bone marrow 
chimeras were generated using lentivirally transduced hematopoietic stem cells. It 
was demonstrated that a 1.7kb fragment of the mouse DC-STAMP promoter 
drives DC-specific transgene expression, which induced both central and 
peripheral tolerance in CD4 and CD8 T cells. In the next step, we made use of this 
model to investigate the role of mature CD8 T cells, which re-enter the thymus. 
These mature re-entering CD8 T cells interfered with negative selection of 
developing T cells with the same specificity by elimination of antigen-presenting 
cells (APCs) in the thymus. This APC elimination was antigen-specific and 
affected both DCs and medullary thymic epithelial cells (mTECs). In addition, we 
investigated mechanisms of transcriptional regulation in DCs. Computational 
comparison of mouse CD11c and DC-STAMP promoter regions across species 
identified common regulatory elements in a defined orientation, the so-called 
CD11c/DC-STAMP promoter model. Mapping of CD11c promoter activity by in 
vivo promoter analysis confirmed the importance of the region, where the 
CD11c/DC-STAMP promoter model was predicted to be located. Screening a 
mouse promoter database for this model resulted in the identification of two novel 
candidate genes, so far not connected to DC biology. It was shown that these two 
genes are expressed in DCs and are partly coregulated with CD11c and DC-
STAMP. In summary, transcriptional targeting of DCs by lentiviral vectors was 
successfully used to address questions regarding immunomodulatory capacity 
and transcriptional regulation of DCs.   
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2 ZUSAMMENFASSUNG 
Dendritische Zellen (DZ) spielen eine wichtige Rolle in der Steuerung der 
angeborenen und adaptiven Immunantwort. Sie sind in spezieller Weise dazu 
geeignet Antigene für T-Zellen zu präsentieren, wobei dies entweder fremde oder 
Selbst-Antigene sein können. DZ exprimieren eine Vielzahl von Rezeptoren, die 
bestimmte Muster auf Pathogenen erkennen und dazu dienen diese in die Zelle 
aufzunehmen. Dabei machen die DZ einen Reifungsprozess durch, der dazu führt, 
dass sie auf potente Weise verschiedenste T-Zell-Antworten auslösen. Wenn die 
DZ hingegen Selbst-Antigen präsentieren, führt dies zu Toleranzentwicklung in 
naiven T-Zellen. In dieser Arbeit haben wir ein lentivirales Gentransfer-System 
mit DZ-spezifischen Promotoren verwendet um verschiedene Fragestellungen 
hinsichtlich der Biologie von DZ in vivo zu behandeln. Dabei wurden 
Knochenmarks-Chimären mit Hilfe von hämatopoetischen Stammzellen generiert, 
die zuvor lentiviral infiziert worden waren. Es wurde gezeigt, dass ein 1.7kb 
großes Fragment des Maus-DC-STAMP-Promotors DZ-spezifische Expression von 
Transgenen steuert, was sowohl zentrale als auch periphere Toleranz in CD4 und 
CD8 T-Zellen auslöste. Anschliessend machten wir uns dieses Model zu Nutze um 
die Rolle von reifen CD8 T-Zellen zu untersuchen, die zurück in den Thymus 
wandern. Dort beeinträchtigten diese reifen CD8 T-Zellen durch die Eliminierung 
Antigen-präsentierender Zellen (APZ) die negative Selektion von sich 
entwickelnden T-Zellen, die dieselbe Spezifität hatten. Die Eliminierung von APZ 
war Antigen-spezifisch and betraf sowohl DZ als auch medulläre thymische 
Epithelzellen. Des Weiteren wurden Mechanismen der transkriptionellen 
Regulation in DZ untersucht. Dazu wurden CD11c und DC-STAMP Promotoren 
verschiedener Spezies mit Hilfe von Bioinformatik verglichen. Dies führte zur 
Identifikation von gemeinsamen regulatorischen Elementen in einer bestimmten 
Orientierung zueinander, dem sogenannten CD11c/DC-STAMP-Promotor-
Modell. Die Aktivität des CD11c Promoters wurde anhand von in vivo 
Promotoranalyse auf diesen Bereich eingegrenzt, in dem das vorhergesagte 
CD11c/DC-STAMP-Promotor-Modell lag. Somit konnte die Wichtigkeit des auf 
bioinformatischen Analysen aufgebauten Modells bestätigt werden. Dann wurde 
eine Datenbank aus Maus-Promotoren nach dem CD11c/DC-STAMP-Promotor-
Modell durchsucht. Dabei wurden zwei Gene identifiziert, die zuvor noch in 
keiner Verbindung zu DZ-Biologie standen. Es wurde gezeigt, dass die beiden 
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Gene in DZ exprimiert und teilweise mit CD11c und DC-STAMP koreguliert 
werden. Transkriptionelles Targeting von DZ durch lentivirale Vektoren wurde 
erfolgreich eingesetzt um Fragen hinsichtlich immunmodulatorischer Fähigkeiten 
und transkriptioneller Regulation von DZ zu behandeln.   
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3 INTRODUCTION 
3.1 Dendritic cells 
Dendritic cells (DCs) play a central role in orchestrating the adaptive immune 
system. They integrate distinct signals and direct the quality of the T cell response 
either towards immunity or tolerance. DCs are localized at body or internal 
surfaces like skin, lung and intestine to monitor for the presence of pathogenic 
invaders and in T cell areas of lymphoid tissues. DCs comprise a very 
heterogeneous cell population that has been characterized with many subsets, 
which differ in location, phenotype and function. In the steady state, DCs migrate 
from peripheral tissues to the draining lymph nodes and present self-antigen to 
naive T cells, inducing tolerance. Upon encounter of pathogen, DCs undergo a 
maturation process, which leads to more pronounced migratory behavior and an 
increase in stimulatory capacity. Depending on the type of pathogen and the 
microenvironmental circumstances, distinct T cell responses are induced resulting 
in protective immunity. 
 
3.1.1 Antigen processing and presentation 
DCs are specialized and very efficient in antigen processing and presentation. 
Inside the cell, protein antigens are processed into peptides and loaded onto 
MHC-molecules. These peptide-MHC (pMHC)-complexes are transported to the 
cell surface, where they are presented to naive T cells. There are two forms of 
antigen processing: the endogenous and the exogenous pathway. In the 
endogenous pathway, proteins that are produced inside the cell are degraded in 
the cytosol by the proteasome and transported via TAP into the ER, where the 
peptides are loaded onto MHC-I molecules. Such proteins include mainly self-
proteins, but also tumor- or virus-associated proteins. MHC-I molecules present 
peptides to CD8 T cells, which differentiate into cytotoxic T lymphocytes (CTL) 
able to eliminate transformed or infected cells.  
The exogenous pathway processes extracellular material, such as antigens derived 
from bacteria, parasites or toxins. One important characteristic of DCs is to react to 
changes in their environment. They are equipped with a variety of receptors, so 
called pattern recognition receptors (PRR) to sense and capture foreign antigen 
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(Ag). These include Toll-like receptors (TLR), Fc-receptors, mannose receptor, 
complement receptors and receptors to bind apoptotic cells. After uptake, these 
antigens enter the endosomal pathway and are subsequently degraded by 
lysosomal proteolysis. In special compartments with low pH, the peptides are 
loaded onto MHC-II molecules and subsequently presented to CD4 T cells. 
In addition to these two pathways described, there is also the possibility that 
exogenous antigen is presented on MHC-I, a process called “cross-presentation”. 
This pathway is of particular importance for the priming of CTLs against tumors 
and viruses that do not infect DCs directly. The molecular mechanism of cross 
presentation is not completely understood, but there is evidence that a specialized 
compartment, the early endosome, favors cross-presentation (1). Moreover, this 
compartment can be specifically targeted, as the mannose receptor mediates 
routing of antigen to this location (2). There is a DC population specialized in 
cross-presentation, in mice characterized by expression of CD8 (see 3.1.5). One 
possible explanation for this unique ability is the fact that in these cells the milieu 
in the early endosomal compartment is specifically regulated to keep it at neutral 
pH (3). This inhibits antigen degradation and allows escape to the cytosol, where 
it is cleaved by the proteasome. Enhanced by TLR stimulation, TAP gets recruited 
to the early endosome and enables the re-import of the generated peptides (4). 
This process circumvents the problem that peptides derived from endocytosed 
material have to compete in the ER with a high number of endogenous peptides 
for MHC-I loading.  
 
3.1.2 DC maturation 
In the classical model, DCs can have two phenotypically distinct states. In the 
immature state, they have high endocytic capability and express low levels of 
MHC-II and costimulatory molecules like CD80, CD86 and CD70 on the surface. 
As a consequence they are inefficient in T cell stimulation, and rather act to induce 
tolerance. In contrast, pathogen encounter induces extensive upregulation of 
MHC-II, costimulatory molecules and chemokine receptors that favor migration to 
lymph nodes, where T cells are effectively primed. This is described as the mature 
state of DCs. Downregulation of endocytosis was previously described as a 
hallmark of DC maturation. Recently, this view has been revised and it is now 
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clear that while mature DCs do indeed show reduced levels of macropinocytosis, 
they retain the ability to capture antigen via receptor-mediated endocytosis (5). 
The strict concept that DC maturation forms the crucial switch between tolerance 
and immunity has also been modified, because there was evidence that DC 
maturation is a continuous process with various outcomes regarding T cell 
responses. The example of IL-12 production (Fig. 1) clearly shows that the 
duration, combination and timing of signals are important for determining the 
stimulatory capacity of the DC (6). Therefore a new terminology based on the 
effector function of the DC has been proposed (7): the classification in tolerogenic 
and immunogenic DCs. 
 
 
 
Figure 1 Signal integration model of DC activation.  
The accumulation of activation signals in DCs results in an increasing capacity to produce IL-12. 
This has a strong impact on the generation of CD4 (Th1) and CD8 effector T cells. TLR Toll-like 
receptor, NLR Nod-like receptor, TEM effector memory T cell, TCM central memory T cell. Adapted 
from (6). 
 
3.1.3 DCs induce immunity 
DCs have the unique ability to prime naive T cells. They are able to upregulate 
costimulatory molecules to levels exceeding those expressed by other antigen 
presenting cells (APC), such as B cells or macrophages. As a consequence, T cells 
get a strong stimulus via CD28 (signal 2) in addition to the TCR signal (signal 1), 
which pushes them over the activation threshold (Fig. 2).  
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Activation of a CD4 T cell leads to upregulation of CD40L, allowing interaction 
with CD40 on the DC, which stimulates the DC to produce cytokines (signal 3). 
Their nature depends on the type of pathogen that the DC had encountered before 
and has an important impact on the further development of the CD4 T cell, known 
as T helper (TH) polarization. Distinct TH cell subsets are classified based on their 
cytokine expression profiles and associated roles for the immune response. TH1 
cells help to clear intracellular pathogens, whereas TH2 cells combat extracellular 
pathogens like parasites and play a role in allergy. A third recently discovered 
subset, the TH17 cell, is important for immune responses against extracellular 
bacteria and fungi and is involved in autoimmune reactions. 
 
 
 
Figure 2 T cell stimulation and polarization requires three DC-derived signals.  
The process in which the TCR recognizes a complex of MHC molecule and cognate peptide is 
defined as signal 1. Signal 2 comprises triggering of CD28 by costimulatory molecules like CD80 or 
CD86, which are upregulated after recognition of PAMPs by PRRs on the DC. Activation by these 
two signals leads to upregulation of CD40L on the CD4 T cell. On the DC, the binding of CD40 
enhances the production of secreted factors (signal 3) that shape the T cell polarization. PAMP, 
pathogen associated molecular pattern; PRR, pattern recognition receptor. Adapted from (8). 
 
The priming of CD8 T cells takes place in a different manner. As the generation of 
cytotoxic T lymphocytes (CTL) poses the risk of autoimmunity, it must be 
carefully regulated. Therefore an additional level of control is put in place: CD8 T 
cells do not express CD40L and cannot stimulate the DC. They rely on CD4 TH 
cells that recognize the same cognate antigen on the DC and “license” it via CD40 
to prime the CD8 T cells (9). As a consequence, CTL survival and memory 
formation are increased. However, in some cases a strong inflammatory stimulus 
can substitute T cell help. Licensed DCs upregulate costimulatory molecules, 
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downregulate inhibitory molecules like PD-L1 and are stimulated to produce 
CCR5 ligands. Recently, an alternative mechanism has been described, in which 
NKT cells provide help in response to glycolipid antigens and trigger DCs to 
produce CCR4 ligands (10). As a result, naive T cells are attracted and can more 
easily find the “right” DC, a concept called guided priming or signal 0 (11).  
 
3.1.4 DCs in tolerance induction 
The immune system has to deal with a tremendous variety of pathogens. To be 
prepared for any possible threat, it generates a large repertoire of T cells with 
many different specificities by TCR gene rearrangement. However, the random 
nature of this process is accompanied by the risk of producing autoreactive TCRs. 
To avoid autoimmune reactions, different mechanisms of tolerance induction are 
employed. 
 
3.1.4.1 Central tolerance 
In the thymus, T cells that develop and react strongly to self-peptide/self-MHC 
complexes are eliminated by a process called “negative selection”. This “quality 
control” should also include all potential self-antigens a T cell might potentially 
encounter in the periphery. However, the expression of some antigens is restricted 
to certain tissues, such as insulin in the pancreas. This problem is solved by 
promiscuous gene expression in medullary thymic epithelial cells (mTECs), a 
process regulated by the autoimmune regulator (AIRE). This transcriptional 
control element recognizes inactive chromatin and induces gene expression by 
recruitment of chromatin remodeling complexes and on the level of pre-mRNA 
processing (12). In addition, it has been described to enhance antigen presentation 
(13). 
Negative selection takes place in the medulla and is mediated by two distinct 
players: DCs and mTECs. Both cell types are equally efficient in clonal deletion of 
CD8 T cells, but there are differences regarding CD4 T cells. Initially, mTECs were 
considered to function merely as antigen reservoirs for DCs, as some findings 
suggested that DCs are necessary for the deletion of CD4 T cells (14, 15). But a 
more recent report showed that mTECs also participate in negative selection (16). 
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Therefore it might depend on the amount or sub-cellular localization of the 
antigen, whether Ag-transfer to a DC is necessary for deletion of CD4 T cells.  
In addition to this mechanism there is a second process to ensure central tolerance: 
CD4 T cells with intermediate TCR affinity are directed to develop into regulatory 
T cells (Treg). For this function, mTECs are essential (17). 
However, central deletion is not complete and the exit of some mature 
autoreactive T cells to the periphery still occurs (18). 
 
3.1.4.2 Peripheral tolerance 
The process of inactivating autoreactive T cells that have escaped thymic deletion 
is known as peripheral tolerance. This can occur through deletion, anergy or 
induction of Tregs. Anergy is defined as an unresponsive, nonproliferative state. 
In contrast, T cells undergoing clonal deletion initially proliferate, but are unable 
to develop effector functions and ultimately die by apoptosis. 
Their potent Ag-presenting properties make DCs an important player in the 
induction of peripheral tolerance. Recent experimental evidence has shown that 
constitutive ablation of DCs indeed results in the generation of autoimmunity (15). 
In the steady state, DCs sample self-antigen and present it in the absence of 
costimulation and proinflammatory cytokines, which results in T cell anergy or 
deletion. When the capacity of DCs to take up antigen is inhibited experimentally, 
autoreactive T cells accumulate in peripheral organs and can cause autoimmune 
disease (19). The amount of antigen has been suggested to be a critical factor 
deciding between the two T cell fates: high levels of antigen mediating a chronic 
high TCR signal favor generation of anergy (20). How the process of tolerance 
induction operates on a molecular level has been addressed by Probst et al (21): 
resting DCs mediate negative signals by triggering inhibitory receptors like PD-1 
and CTLA-4 on CD8 T cells. However, on CD4 T cells, expression of ICOS 
(inducible costimulator) has been described to be necessary for the induction of 
anergy (22). The molecular basis for clonal deletion of CD8 T cells is characterized 
by Bim-upregulation and decreased levels of Bcl-2 and IL-7R α chain (23). 
Notably, there were overlaps observed in the molecular signatures of T cells 
undergoing deletional apoptosis or anergy. 
Another mechanism by which DCs promote tolerogenic responses involves the 
production of IDO (indoleamine 2,3- dioxygenase), which is induced via 
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interaction with CTLA-4. On the one hand, this enzyme catalyzes the degradation 
of the essential amino acid tryptophan, which results in the inhibition of T cell 
proliferation. As a second effect, metabolic products of this pathway promote the 
induction of T cell apoptosis (24).   
The generation or expansion of Tregs presents an indirect way to induce 
peripheral tolerance, as this cell type is specialized in the suppression of T cell 
responses, e.g. through secretion of the immunoregulatory cytokines IL-10 and 
TGF-β. One distinguishes between natural Tregs, which are generated in the 
thymus, and induced Tregs (iTregs) that develop from naive CD4 T cells in the 
periphery. For the generation of iTregs, DCs produce factors like TGF-β, IL-10 and 
retinoic acid. Tregs in turn constitutively express CTLA-4, which induces down 
modulation of costimulatory molecules on DCs (25). This interferes with 
subsequent activation of other T cells, promoting the tolerogenic phenotype of the 
DC. 
 
3.1.5 DC subsets 
There are several types of DCs, each characterized by different cellular markers 
and functions. A first distinction can be made between plasmacytoid and 
conventional DCs. Plasmacytoid DCs (pDC) express the B cell marker B220 and 
are present in primary and secondary lymphoid organs as well as in blood. They 
are specialized in the response to viruses, as they express a set of intracellular 
PRRs recognizing viral nucleic acids and can produce high levels of type I 
interferon.  
Conventional DCs can be further divided into migratory and lymphoid resident 
DCs. Migratory DCs are originally located in peripheral tissues such as skin, lung 
and intestine, where they act as sentinels and a first-line of defense against 
pathogenic invaders. Via the lymphatics, they enter the draining lymph nodes, 
where they directly present antigen to T cells or transfer it to lymph node resident 
DC populations (26). The best-studied example for migratory DCs are Langerhans 
cells from the epidermis. 
In the mouse, lymphoid resident DCs are classified as either CD8 positive or 
negative DCs. The latter express CD11b and are mainly involved in the priming of 
CD4 T cells (27). The CD8 positive DC subset is the main producer of IL-12, 
thereby driving TH1 development and promoting CD8 T cell responses (28). The 
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most outstanding feature of the CD8 positive DCs is their ability to cross-present 
antigen, which is necessary to exert two opposing functions. On the one hand, it 
allows priming of CTLs against viruses that do not directly infect DCs, while on 
the other hand, it induces CD8 T cell tolerance against self-Ag that is only 
expressed in certain tissues and not by DCs themselves (19). Supporting these 
functions, Clec9A, a receptor for necrotic cells, is preferentially expressed by the 
CD8 positive DC subset (29). In addition, only the CD8 positive DC subset is able 
to produce high amounts of TGF-β and thereby mediate the generation of iTregs 
(30). In contrast, CD8 negative DCs have a higher capability to support the 
expansion of natural Tregs. 
As the CD8 positive DC subset has these special functions, the definition of a 
human equivalent was an important task, but unfortunately no CD8 expressing 
DC subset has been found in humans. However, the XC chemokine receptor 1 
(XCR1) was recently identified as a common marker for the DC population 
specialized in cross-presentation (31). Expression of XCR1 could help to amplify 
CD8 T cell responses. After antigen recognition CD8 T cells start to produce XCL1, 
the ligand for XCR1, potentially recruiting CD8 positive DCs to the site of first 
antigen encounter (32). 
 
The “division of labor” regarding cross-presentation between DC subsets has 
important consequences: activated CTLs are able to kill DCs in an Ag-dependent 
fashion in peripheral tissues (33) and lymph nodes (34). This inhibits the 
generation of new CTLs specific for the same antigen, providing negative 
feedback regulation, but does not compromise the activity of the CTL itself. In 
contrast to CD4 T cells, activated CTLs function on “autopilot”(35) and do not 
need continuous presence of antigen or stimulation by DCs. If all DCs were able to 
cross-present, they would all be eliminated by antigen-specific CTLs during a 
systemic viral infection. However, the existence of multiple DC subsets means that 
there are still other DCs available that can maintain TH cell responses important 
for antibody production and macrophage activation (36). 
 
Another example of division of labor between different DC subsets within the 
same organ can be observed in the gut. CD103 positive DCs have tolerogenic 
capacity, in that they induce Treg cells, whereas the CD103 negative subset is the 
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main producer of proinflammatory cytokines and generates protective immunity 
to pathogens (37). 
 
Finally, another population of DCs has been described to emerge during systemic 
inflammation: monocytes can develop into inflammatory DCs, termed TIP-DCs, as 
they mainly produce TNF and inducible nitric oxide synthase (38). 
 
3.1.6 DCs in immunotherapy 
The ability to orchestrate both arms of immunology, protective immunity and self-
tolerance, makes DCs attractive targets for immunotherapy. DCs can be used to 
boost immune responses against pathogens or tumors as well as to dampen 
undesired immune activity such as autoimmunity, allergy or transplant rejection. 
Currently, two DC-based immune therapy approaches are followed in preclinical 
and clinical studies: 
 
In vivo targeting of DCs  
This method involves the direct injection of DC-specific monoclonal antibodies 
coupled to Ag. It offers the possibility to specifically target the DC subset of 
choice, as they differ in their surface receptors (e.g. DEC-205 on CD8 positive DCs 
and the 33D1 Ag on CD8 negative DCs in mice). There is preclinical evidence that 
Ag-targeting to DEC-205 in the absence of a maturation stimulus results in 
tolerance induction (39), whereas using a similar antibody with an adjuvant has 
been found to improve cellular and humoral immune responses against a HIV-Ag 
(40). 
 
Ex vivo manipulation of DCs 
Cells from donor blood are used ex vivo to generate DCs, which are manipulated 
by Ag-loading and subsequently injected into the patient. In culture, the process of 
Ag-loading and maturation can be tightly controlled, but it is necessary to 
generate high cell numbers, which is very cost intensive. In clinical trials using 
DCs loaded with tumor Ag, durable complete clinical responses were elicited in a 
small number of patients with metastatic melanoma (41, 42). 
Another therapeutic possibility is gene transfer, which can be carried out by 
transfection of nucleic acids or by viral transduction (see 3.2). In mouse models, 
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tolerogenic effects were achieved by adenoviral transfer of soluble TNF receptor 
(43) or IL-10 (44) into DCs, which resulted in prolonged allograft survival. 
Lentiviral transfer of a neuropeptide into DCs also induced a tolerogenic 
phenotype, which was demonstrated to be beneficial in autoimmunity models 
(45). 
Different cell types can be infected and genetically modified: ex vivo DCs or 
hematopoietic stem cells (HSCs) that can also give rise to DCs in the recipient. The 
latter method has the advantages that the DCs are not directly exposed to 
manipulation, which could change their phenotype, and that natural DC subsets 
are involved instead of the artificially generated in vitro DC type.  
 
3.2 Gene therapy 
Gene transfer can be used to treat diseases, an approach known as gene therapy. 
As some diseases are caused by mutation of a single gene, this offers the 
possibility to cure the patient by transfer of the original gene sequence to restore 
its function. For this purpose viral vectors are particularly suitable, because it is 
part of their life cycle to enter a cell. These vectors can be used to transduce HSCs 
or other cell types, which are subsequently transferred back into the patient. To 
ensure long-term benefits for patients, stable gene delivery is necessary and 
desirable. Retroviruses meet this requirement with their unique ability to integrate 
into the host cell genome. As a result, the introduced genetic information is 
constantly passed on to daughter cells during cell division. In addition, retroviral 
vectors are characterized by having a very low immunogenicity in comparison to 
adenoviral vectors. 
Gene therapy using retroviral vectors has been efficiently applied for various 
human diseases. These include the lymphocyte linked severe combined 
immunodeficiency (SCID) (46, 47), the phagocyte linked immunodeficiency 
chronic granulomatous disease (CGD) (48), the metabolic disorder 
adrenoleukodystrophy (49) and the blood disorder β-thallasemia (50). Also in 
cancer treatment a gene therapy approach can be used to engineer T cells to 
express tumor-specific receptors, which has been successfully used in cases of 
neuroblastoma (51). 
For gene therapy approaches, two members of the retroviral family have mainly 
been used: γ-retroviruses and lentiviruses. They differ in the mode of integration 
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site selection. Both favor transcriptionally active regions, but γ-retroviruses have a 
particular preference for transcriptional start sites. This process bears the risk that 
downstream proto-oncogenes are activated, which can lead to tumorigenesis. 
Unfortunately, cancer development has indeed been observed in some patients 
after gene therapy treatment. However, there is evidence that lentiviral vectors 
display a less harmful distribution of chromosomal integrations (52) and have 
another major advantage over γ-retroviruses: the unique ability to infect non-
dividing target cells. 
The risk of tumorigenesis is the major drawback of gene therapy. The 
development of novel improved vectors is focused on attempting to avoid this: 
e.g. chromatin insulators, which flank the integrating sequence are used to make 
integration safer (53) and some progress is currently being made in the 
development of non-integrating lentiviral vectors (54). 
 
3.2.1 Gene transfer by lentiviral vectors 
In this study, we applied lentiviral gene transfer to address questions of DC 
biology in vivo. The lentiviral vectors we used for experimentation are derived 
from the human immunodeficiency virus (HIV)-1. This virus belongs to the family 
of retroviruses, which contain a single-stranded RNA genome that is reverse 
transcribed into double-stranded DNA before integration into the host cell 
genome. The HIV-1 genome is composed of regulatory, accessory and structural 
genes with different functions (Table 1). 
Before the HIV-1 vector was first used for experimental gene transfer into cells, 
several modifications were introduced in order to increase biosafety (55) . To this 
end, the genetic information was separated into two plasmids (Fig. 3), which are 
transiently cotransfected into a producer cell line. The transfer vector contains an 
expression cassette with the transgene of interest under the control of an internal 
promoter, which is flanked by long terminal repeats (LTRs). The LTRs are 
composed of an U3, R and U5 region. The U3 region contains the viral promoter 
elements, whereas the R and U5 regions are required for reverse transcription. All 
relevant HIV-1 proteins are encoded by the packaging plasmid regulated by a 
CMV promoter. The fact that only the transfer vector contains the packaging 
signal (Ψ), which ensures transfer into the viral capsid, renders the virus 
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replication-deficient: after infection the genetic information for all viral proteins is 
missing in the host cell.  
  
Table 1  HIV-1 genes and gene products with their respective functions.  
Some genes encode for polyproteins that are subsequently cleaved. Modified from (55). 
Gene Encoded protein (s) Function  
Regulatory genes 
tat 
 
rev 
 
 
Tat 
 
Rev 
 
 
 
trans-activation of gene expression 
 
nuclear export of late mRNAs, promotion of 
polysomal binding to RRE-containing RNAs 
Accessory genes 
vif 
 
vpr 
 
 
vpu 
 
 
nef 
 
Vif 
 
Vpr 
 
Vpu 
 
Nef 
 
enhancement of virus transmission 
 
nuclear transport of proviral DNA, 
induction of G2 arrest in dividing cells 
 
CD4 degradation,  
virus maturation and release 
 
CD4 and MHC-I down regulation, 
enhancement of virus replication 
Structural genes 
Gag 
 
 
pol 
 
 
env 
 
matrix, capsid, 
nucleocapsid, p6 
 
reverse transcriptase, 
integrase, protease 
 
gp120, gp41 
 
formation of viral particles, 
packaging of viral genomic RNA 
 
reverse transcription, integration and virion 
maturation 
 
binding and entry into the host cell  
 
The env gene encoding the envelope proteins has been deleted from the viral 
genome, as these proteins bind preferentially CD4 on T cells and this is impractical 
for an experimental approach, in which all cells should be targeted. Therefore the 
lentivirus is associated with a different surface glycoprotein: it is “pseudotyped” 
with the glycoprotein of vesicular stomatitis virus (VSV-G), which mediates a 
broad cell tropism, potentially through binding of phosphatidylserine (PS) in cell 
membranes. However, a recent report showed that PS is not the cell surface 
receptor for VSV-G, but is rather involved in a step after viral entry (56). The 
genetic information for VSV-G is supplied on a third plasmid under the control of 
a CMV (cytomegalovirus) promoter (Fig. 3).  
Besides the env gene, the vpu gene was also deleted in the first generation vector 
system (Fig. 3a). As it has been shown that none of the accessory genes of HIV-1 
were necessary for the lentiviral life cycle, they were deleted as well (second 
generation vector system, Fig. 3b). In the next step, the tat gene was also deleted 
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and only gag, pol and rev remained, whereby for biosafety reasons the latter was 
separated on another plasmid (Fig. 3c). Furthermore, the LTRs in the transfer 
vector were modified in the third generation vector system: a deletion was 
introduced into the U3 region (∆U3) of the 3’ LTR, which serves as template for 
the U3 in the 5’ LTR during reverse transcription. As a result, the promoter 
activity of the 5’ LTR is abolished, a process defined as self-inactivation. Moreover, 
the U3 in the 5’ LTR was replaced by a CMV promoter, which prevents 
replacement of the ∆U3 in the 3’ LTR by homologous recombination. Finally, the 
woodchuck post-transcriptional response element (WPRE) was included in the 
transfer vector, which improves transgene expression levels by enhancement of 3’-
end processing and polyadenylation. In this study, the following three plasmids 
were transiently co-transfected into the producer cell line for generation of 
lentivirus: the envelope plasmid together with the packaging plasmid of a second 
generation system and the SIN transfer vector (red boxes in Fig. 3). 
 
 
 
Figure 3 Schematic representation of various lentiviral vector systems. 
All systems use the VSV-G envelope glycoprotein for pseudotyping. The packaging constructs 
differ in the amount of attenuation, HIV-1 genes have been consecutively deleted. CMV, 
cytomegalovirus; Ψ, packaging signal; RRE, Rev response element; LTR, long terminal repeat; 
cPPT, central polypurine tract; W, WPRE woodchuck hepatitis virus post-transcriptional 
regulatory element; SD, splice donor site; SA, splice acceptor site. Modified from (55). 
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In particular, internal promoters with the potential to drive gene expression in 
DCs were used and analyzed for tissue specificity. 
Lentiviral supernatants were used to infect hematopoietic stem cells (HSCs), 
which had been enriched prior to use by 5-FU (5-Fluoro-uracil) treatment of bone 
marrow donor mice (Fig. 4).  
 
 
 
Figure 4 Generation of bone marrow chimeras. 
Donor mice were injected i.v. with 5-FU (5-Fluoro-uracil). Four days later bones were taken and 
bone marrow containing mainly HSCs was isolated. After incubation for 72 h in the presence of a 
stimulating cytokine cocktail, cells were transduced with lentivirus and subsequently injected into 
lethally irradiated recipient mice.  
 
Upon generation of a viral DNA genome through reverse transcription the 5’ LTR 
is replaced by the non-functional 3’ LTR (∆U3). As a consequence, the viral 
promoter is inactivated and only the internal promoter region is active in infected 
cells. After transduction, the virus is removed and the infected HSCs are 
subsequently injected into lethally irradiated mice, which are then analyzed after 8 
weeks to allow full reconstitution of the immune system. 
 
3.3 Aims of the project 
3.3.1 Development of a DC-specific lentiviral vector for 
long-term induction of antigen-specific tolerance 
In humans it has been demonstrated that Ag-specific tolerance can be induced by 
injection of immature peptide-loaded DCs (57), but that effect only lasted for 6 
months (58). Disadvantages of this procedure are not only the short duration but 
also undesired changes in the DC phenotype by ex vivo manipulation. To solve 
these problems we decided to use a model, in which HSCs are transduced by a 
lentiviral vector before injection into the recipient. The ability of lentiviruses to 
integrate into the genome ensures long-term modification and HSCs provide a 
constant source for genetically modified DCs, which can develop without direct 
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manipulation. In order to restrict antigen expression to DCs, a lentiviral vector 
with a DC-specific promoter should be used. 
 
3.3.2 Investigating the role of peripheral T cells in negative 
selection 
Primarily, the thymus is considered to be a generative organ, where progenitor 
cells enter and leave after several stages of development as mature CD4 or CD8 
single positive (SP) T cells. More recently, several reports showed that 'back-
migration' can also occur and mature peripheral T cells may re-enter the thymus 
(59-62). Apparently around 105 mature T cells from the periphery can be 
accommodated in a specific thymic niche (60) and mainly localize to the medulla 
(63). Multiple possible functions have been assigned to these cells, such as 
maintenance of medullary thymic epithelial cells (mTEC) or direct mediation of 
thymocyte selection in certain experimental settings (64-67). None of these 
observed effects are “classical” functions for T cells and were therefore discussed 
as “epiphenomena” (59). Peripheral T cells, which re-enter the thymus of normal 
mice, are not naive but rather activated and cycling (68). Upon activation, T cells 
change their homing receptors in order to mediate effector functions in all tissues 
of the body, including the thymus (63).  
In lymph nodes (34) and tissues (33) cytotoxic effector T cells can eliminate 
dendritic cells (DCs) in an antigen-specific manner. We wanted to investigate, 
whether peripheral T cells can also remove APCs upon return into the thymus and 
thereby potentially alter negative selection. 
 
3.3.3 In vivo promoter analysis 
Dendritic cells (DCs) have a variety of biological features. We wanted to know 
how these are regulated on a transcriptional level and define relevant DC-specific 
regulatory transcriptional networks. One important characteristic of DCs is to 
sense and react to changes in their environment. This makes conventional 
promoter analysis studies difficult to perform, as DCs quickly alter their 
phenotype in response to in vitro manipulation. We used a novel method for 
promoter analyses, in which HSCs are genetically manipulated by lentiviral 
vectors and expression of the reporter gene is monitored in various primary cell 
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types, which develop without further manipulation in irradiated recipient mice. In 
addition, comparative promoter analysis by computational means was employed 
to define evolutionary conserved regions within promoter sequences. 
Furthermore, the characterization of regulatory elements within the mouse CD11c 
promoter could help to identify a smaller and still functional promoter fragment. 
As lentiviral vectors have size limitations, this could be of use for future cases, in 
which transgenes with greater length are inserted behind the promoter. 
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4 MATERIALS AND METHODS 
Both materials and methods are listed alphabetically. Company headquarters are 
only indicated at first mention. 
 
4.1 Materials 
4.1.1  Antibodies 
Table 2  Antibodies used in flow cytometry.  
Specificity 
(anti-mouse) 
Conjugate Clone Supplier 
B220 PerCP RA3-6B2 Becton, Dickinson & Co. (BD), 
Franklin Lakes, NJ, USA  
CD3 PerCP 145-2C11 BD  
CD4 PE 
PerCP 
PE-Cy7 
GK1.5 BD  
CD8 PE 
PerCP 
APC-Cy7 
53-6.7 BD  
CD11b PE M1/70 BD 
CD11c APC HL3 BD 
CD19 PerCP 
PE-Cy7 
1D3 BD 
CD24 PE M1/69 BD 
CD25 FITC PC61 BD 
CD44 PE Pgp-1, Ly-24 BD 
Alexa Fluor 
405 
IM7.8.1 life technologies, Carlsbad, 
CA, USA  
CD45.1 APC 
eFluor 450 
A20 eBioscience, San Diego, CA, 
USA 
CD62L PE Mel-14 BD 
CD69 PE H1.2F3 BD 
 
27 
 
Streptavidin-APC was purchased from life technologies and Streptavidin-PE from 
Southern Biotec. The MHC tetramers H-2Kb/SIINFEKL (OVA257-264) and                  
H-2Kb/SSIEFARL (HSVgB498-505) were either directly PE-labeled or used in 
combination with a PE-Fluorotag and were purchased from ProImmune (Oxford, 
UK). 
 
4.1.2 Chemicals 
If not stated differently, chemicals were purchased from Merck (Darmstadt, 
Germany), Roth (Karlsruhe, Germany) or Sigma-Aldrich (St. Louis, MO, USA). All 
buffers and solutions were prepared using double distilled water. 
CD90.1 FITC 
PerCP 
OX-7 BD 
F4/80 PE BM8 BD 
Gr-1 PE RB6-8C5 BD 
I-Ab PE AF6-120.1 BD 
IFNγ PE 
APC 
XMG1.2 BD 
κ chain PE polyclonal Southern Biotec (Birmingham, 
AL, USA) 
λ chain PE polyclonal Southern Biotec (Birmingham, 
AL, USA) 
Ly6C FITC AL-21 BD 
Neutrophils Biotin 7/4 AbD Serotec (Oxford, UK) 
NK1.1 PE 
PE-Cy7 
PK136 BD 
PD-1 FITC J43 BD 
Qa-2 Biotin 1-1-2 BD 
TNFα FITC 
PE 
MP6-XT3 BD 
Vα2 TCR FITC 
APC 
B20.1 BD 
Vβ5.1/5.2 
TCR 
FITC 
PE 
MR9-4 BD 
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4.1.3 Consumables 
Centricon filter    Millipore Corporation, Billerica, MA, USA 
disposable syringe filter    Nalgene Nunc Int., Rochester, NJ, USA 
(0.2 + 0.45 µm)  
bottle filter      Nalgene Nunc Int. Rochester, NJ, USA  
disposable injection needle  Terumo Medical Corporation, Tokyo, 
Japan (26 G x 1/2“) 
disposable syringe (1+5 ml)  Braun, Melsungen, Germany  
reaction container 0.2 ml    Nunc, Wiesbaden, Germany 
reaction container 1.5 ml und 2 ml  Eppendorf, Hamburg, Germany  
reaction tube 5 ml   BD, Franklin Lakes, NJ, USA 
reaction tube 15 ml und 50 ml   Greiner, Frickenhausen, Germany 
 
Other materials and plastic wares were purchased from BD, Nunc (Wiesbaden, 
Germany) and Greiner (Frickenhausen, Germany). 
 
4.1.4 Devices 
Analytic scale (Adventurer, Ohaus Corp., Pine Brooks, NJ, USA), automatic 
pipettors (Integra Biosciences, Baar, Switzerland), bench centrifuge (Centrifuge 
5415 D, Eppendorf, Hamburg, Germany), cell counter (Coulter Counter Z2, 
Beckman Coulter, Krefeld, Germany), centrifuge (Rotixa RP, Hettich, Tuttlingen, 
Germany), chemical scale (Kern, Albstadt, Germany), flow cytometer 
(FACSCalibur, FACSCantoII and FACSAria, BD), incubator (Hera cell, Heraeus 
Kendro Laboratory Products, Hanau, Germany), laminar airflow cabinet 
(Heraeus), magnetic stirrer (Ika Labortechnik, Staufen, Germany), PCR-machine 
(Biometra, Goettingen, Germany), pH-meter (Inolab, Weilheim, Germany), 
pipettes (Gilson, Middleton, WI, USA), power supply (Amersham Pharmacia, 
Piscataway, NJ, USA), real-time PCR machine (Lightcycler, Roche, Basel, 
Switzerland or CFX96 Real Time System, BIO-RAD, Hercules, CA, USA), vacuum 
pump (KNF Neuberger, Munzingen, Germany), vortex-Genie2 (Scientific 
Industries, Bohemia, NY, USA), water bath (Grant Instruments Ltd., Barrington 
Cambridge, UK). All other devices are mentioned in the methods section. 
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4.1.5 Media and solutions 
ACK buffer       8.29 g NH4Cl  
       1 g KHCO3  
       37.2 mg Na2EDTA  
       H2O ad 1 l  
pH 7.2-7.4 adjusted with 1 N HCl 
sterilized by 0.2 µm filtration 
 
PBS       150 mM NaCl  
       10 mM Na2HPO4  
       2 mM KH2PO4  
       pH 7.4 adjusted with 5 N NaOH  
 
PBS-FBS      Dulbecco’s PBS without Ca2+/Mg2+  
2% FBS (v/v)  
  
FACS buffer      PBS  
       2% FBS (v/v)  
       0.01% NaN3 (v/v)  
 
5-Fluoro-uracil (5-FU)            20 mg/ml in Dulbecco’s PBS  
               pH 10-11 adjusted with NaOH  
               vortex until complete dilution 
               pH 7.5 adjusted with HCl  
               Sterilized by 0.2 µm filtration  
               Stored at –20°C 
 
MACS buffer     Dulbecco’s PBS without Ca2+/Mg2+  
       0.5% FBS (v/v)  
       2 mM EDTA  
 
RFI               15% Glycerin (v/v) 
               100 mM KCl 
             50 mM MnCl2 
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             30 mM C2H3KO2 
             10 mM CaCl2 
pH 5.8 adjusted with 0.2 mM acetic 
acid 
               Sterilized by 0.2 µm filtration  
               Stored at 4°C  
 
RFII              15% Glycerin (v/v) 
              10 mM MOPS 
              10 mM KCl 
              75 mM CaCl2 
           pH 6.8 adjusted with 1 N NaOH  
              Sterilized by 0.2 µm filtration  
               Stored at 4°C 
 
50x TAE buffer     242 g Tris 
       57.1 ml 100% acetic acid (v/v) 
           100 ml 0,5 M EDTA (pH 8.0) 
       H2O ad 1 l 
 
Solutions used for transfection 
2xHBS             50 mM HEPES 
              280 mM NaCl 
              1.5 mM Na2HPO4-Dihydrate 
              pH 7.05 adjusted with NaOH  
              Sterilized by 0.2 µm filtration  
       Stored at –20°C (≤ 6 months) 
 
CaCl2               2.5 M CaCl2 
               Sterilized by 0.2 µm filtration  
               Stored at –20°C  
 
Cell culture media 
All culture media and solutions were purchased from Gibco (Invitrogen, Carlsbad, 
CA, USA) unless otherwise stated. 
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DC medium            RPMI 1640 + glutamine 
       (PAA, Pasching, Austria) 
          5% FBS (inactivated, v/v) 
          500 mM β-mercaptoethanol 
          100 U/ml penicillin 
             100 µg/ml streptomycin 
             25 ng/ml GM-CSF  
 
HSC medium Stemline II hematopoietic stem cell 
expansion medium 
             (Sigma-Aldrich)  
             100 U/ml penicillin 
             100 µg/ml streptomycin 
             50 ng/ml hIL-6  
             10 ng/ml mIL-3 
             50 ng/ml mSCF 
 
293FT medium Dulbecco’s Modified Eagle 
Medium (DMEM) with glutamax-I 
10% FBS (inactivated, v/v) 
            100 U/ml penicillin 
            100 µg/ml streptomycin 
0.1 mM non-essential amino acids 
(MEM)          
10 mM HEPES 
            500 µg/ml geneticin 
             
293FT transfection medium same as 293FT medium, without 
geneticin 
 
NIH3T3 medium      DMEM 
10 % FBS (non-inactivated, v/v) 
100 U/ml penicillin 
       100 µg/ml streptomycin 
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Freezing medium           90% FBS 
             10% DMSO 
 
4.1.6 Mouse strains 
All mice were bred and maintained in the mouse facility of the Institute of 
Immunology (LMU, Munich, Germany). 
 
C57BL/6 (B6)  
This inbred strain has the MHC-haplotype H-2b. Mice from the C57BL/6 strain 
express the allele Ly5.2 (CD45.2) on all leukocytes and Thy1.2 (CD90.2) on all T 
cells. Two congenic strains were also used that either express Ly5.1 (CD45.1) or 
Thy1.1 (CD90.1) on a B6 background.  
 
OT-I 
CD8 T cells from OT-I mice express the transgenic Vα2/Vβ5 TCR specific for OVA 
(ovalbumin)257–264 in the context of MHC-I H-2Kb (69). These mice were kept on a 
B6 background either expressing the Ly5.1 or the Thy1.1 allele. 
 
OT-II  
CD4 T cells from OT-II mice (70) express the transgenic Vα2/Vβ5 TCR specific for 
OVA323-339 that is recognized in the context of MHC-II I-Ab (71). These mice 
expressed the congenic marker Thy1.1 on a B6 background. 
 
RIP-mOVA 
RIP-mOVA mice express a membrane-bound form of OVA under control of the 
rat insulin promoter (RIP) (72). In the pancreas and testis of these mice OVA is 
expressed as a model auto-antigen. When RIP-mOVA mice receive OT-I T cells by 
adoptive transfer and are immunized, they develop diabetes (73). The progress of 
diabetes is monitored by measuring the glucose concentration in the urine (Diabur 
5000, Roche). 
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4.1.7 Peptides, protein and oligonucleotides 
The peptides OVA257-264 and HSVgB498-505 were purchased from PolyPeptide Group 
(Strasbourg, France). Ovalbumin (albumin from chicken egg white, Grade V) was 
purchased from Sigma-Aldrich.  
Oligonucleotides were purchased from MWG-Biotech AG (Ebersberg, Germany) 
and are indicated in the relevant context in the methods section. Sequencing 
reactions were carried out by Sequiserve (Vaterstetten, Germany) or MWG-
Biotech AG. 
 
4.1.8 Vectors 
Cloning vector  
For subcloning, the plasmid pBluescript-II-KS+ (pBS, Agilent Technologies, Santa 
Clara, CA, USA) was used. 
 
Herpes Simplex vector 
The recombinant, replication deficient HSV-1 vector HSV-OVA was produced by 
P. Marconi (University of Ferrara, Italy). It is based on T0ZGFP, a low toxicity 
HSV vector, in which three immediate early genes are deleted. The hCMV-β-
Globin-OVA expression cassette has been inserted into the UL41 locus (74). 
 
Lentiviral vectors 
All lentiviral vectors used in this work are based on FUGW (75). In this vector, as 
described above, the promoter/enhancer-containing region localized in the 3’LTR 
is deleted. As a result, the virus is inactivated after integration and replication is 
blocked. For all cloning reactions the FUGW vector was digested with Pac I and 
Age I to remove the original Ubiquitin C promoter. The mouse CD11c promoter 
sizes 2000bp and 1500bp correspond to the restriction sites Hind III and SexA I 
within the 5kb promoter, respectively. Initially, the 1000bp fragment was 
amplified by PCR with 5’-ATTTGCGGCCGCTAGCACCCCAGTTCTTTGCT-3’ 
and 5’-TCGCGACTGCAGCCCACTGGAGAA-3’ primers and cloned into a 
different vector with Not I and Nru I. From there it was isolated with Not I, the 
sticky end was filled up by Klenow enzyme, and with Age I. This fragment was 
ligated into the FUGW, which has been treated with Pac I, Klenow enzyme and 
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Age I. To generate the smaller mouse CD11c promoter-GFP constructs, various 
promoter fragments were amplified using standard PCR. The following primers 
were used: 900 5’-CCTTAATTAACAATGCTTACCCCACCCCCTC-3’, 750 5’-
CCTTAATTAACAGTTTTTAGTATTCTCTTGACCTTGG-3’, 500 5’-GCTATTAAT 
TAATATGTTGAGCAAATGACTAAT-3’, 400 5’-GCTATTAATTAATGTGCTTAC 
TTCTTAGTCTACTTCCA-3’ with the same reverse primer 5’-
GCATACCGGTCGACTGGAGAACAGAAGCA-3’ for all of the constructs. The 
minimal SV40 promoter was amplified from the pGL3-Promoter vector (Promega, 
Madison, WI, USA) using the primers 5’-CCTTAATTAAGCGATCTGCATCTCAA 
TT-3’ and 5’-GCATACCGGTGCCAAGCTTTTTGCAAAAGC-3’. To combine the 
CD11c promoter fragments with the minimal SV40 promoter, the fragments were 
amplified by PCR (CD11c500-400bp 5’-CCGCTCGAGCGGTATGTTGAGCAAATGAC-
3’ and 5’-GGAAGATCTTCCTGATCCATGTAGGGAGC-3’, CD11c750-574bp 5’-
CTAGCTAGCATTGCTTCTGAAATTCAG-3’ and 5’-GAAGATCTGAGTAAAAG 
CAGATGG-3’, CD11c750-400bp 5’- CTAGCTAGCATTGCTTCTGAAATTCAG-3’ and 
5’-GGAAGATCTTCCTGATCCATGTAGGGAGC-3’) and cloned first into the 
pGL3-Promoter vector using the following restriction enzymes: Xho I and Bgl II 
(CD11c500-400bp) or Nhe I and Bgl II (CD11c750-574bp, CD11c750-400bp). In the next step the 
CD11c fragments were isolated together with the minimal SV40 promoter: Sma I 
and Hind III for CD11c500-400bp or Nhe I and Hind III for CD11c750-574bp and  
CD11c750-400bp. All these fragments were completely blunt-ended and ligated into a 
blunt-ended FUGW. All CD11c-GFP constructs were validated by sequencing.  
 
For this work also other lentiviral constructs were used, which have been 
previously described (76): 
The DC-STAMP-OVA virus contains a membrane bound form of ovalbumin 
(fused to the membrane part of the transferrin receptor) under the control of a 
1704bp promoter fragment of mouse DC-STAMP. Specificity of the relevant 
promoter fragment was first analyzed with a lentiviral vector containing GFP as a 
reporter gene (DC-STAMP-GFP). As control virus a modified form of FUGW was 
used, which contains the Ubiquitin C promoter without any transgene.  
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4.2 Methods 
4.2.1 Cellular and immunological methods 
4.2.1.1 Adoptive cell transfer 
This method involves transfer of T cells from a donor mouse into a recipient 
mouse. T cells were isolated from spleens and/or lymph nodes of donor mice 
using negative selection (MACS, see 4.2.1.10). The purity of T cells was 
determined by flow cytometry (see 4.2.1.5.) before i.v. transfer into syngenic 
recipients of the same sex. Congenic markers (Ly5.1 or Thy1.1) allowed 
subsequent detection of transferred T cells in the recipient. 
 
4.2.1.2 Cell culture 
Culture and lentiviral transduction of hematopoietic stem cells (HSC) 
Donor mice were injected i.v. with 5-Fluorouracil (5-FU, 150 mg/kg body weight, 
Invivogen, San Diego, CA, USA), after four days mice were sacrificed and bone 
marrow was isolated. 5-FU is a pyrimidin analog, which inhibits DNA synthesis 
and therefore leads to apoptosis of proliferating cells. Thereby 5-FU treatment 
enriches the non-dividing stem cell population in the bone marrow. The cell 
suspension was depleted of erythrocytes (Mouse Erythrocyte Lysing Kit, R&D 
Systems, Minneapolis, MN, USA), resuspended in HSC medium (1x106 cells/ml) 
and cultured in 100 mm plates at 37°C and 5% CO2. The cells were stimulated with 
a cytokine mixture (Miltenyi Biotec, Bergisch Gladbach, Germany) containing 
murine IL-3 (10 ng/ml), murine SCF (50 ng/ml) and human IL-6 (50 ng/ml). At 
day 3 of culture cells were spin-infected (300 g, 2 h at 32°C) with cell-free stocks of 
lentivirus (MOI between 0.2 and 5) in the presence of protamine sulfate (4 µg/ml, 
Sigma-Aldrich). After four more hours incubation at 37°C the virus was removed, 
cells were incubated in HSC medium and 1-3x106 cells per recipient mouse were 
injected i.v. in PBS the next day.  
 
Culture of dendritic cells 
Addition of the cytokine GM-CSF leads to in vitro differentiation of DCs from bone 
marrow in the course of several days. A modified version of Inaba’s protocol (77) 
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was used. Bone marrow cells were depleted of erythrocytes (Mouse Erythrocyte 
Lysing Kit, R&D Systems) and 1x106 cells/ml were cultured in DC-medium in a 
total amount of 10 ml per 100 mm plate at 37°C and 5% CO2. Each 2-3 days fresh 
medium was added. If desired, lentiviral transduction was performed at day 1 of 
culture with 1x106 cells/ml, in a total of 2 ml per well in a 6 well plate. The 
transduction protocol was the same as for NIH3T3 cells (see below).  
 
Culture of 293FT and NIH3T3 cells 
293FT (human embryonic kidney cell line) and NIH3T3 (mouse embryonic 
fibroblast cell line) cells were cultured in their respective media at 37°C and 10% 
CO2. They were kept in 175 cm2 and 75 cm2 tissue culture flasks, respectively. Both 
cell lines were split every other day taking care that less then 75% confluence was 
reached.  
 
Transduction of NIH3T3 cells for lentivirus titration 
NIH3T3 cells were plated with 4x104 cells/well in 24-well plates 18 h before 
transduction. A total of 6 wells were prepared per virus to be titrated. Two 
additional wells were plated to determine the number of cells per well at the time 
of transduction. Using NIH3T3 medium, different dilutions were made depending 
on the virus stock: for concentrated virus dilutions between 1/100 and 1/10000 
were adequate, whereas for unconcentrated virus dilutions between 1/5 and 
1/100 were used. NIH3T3 cells were transduced with 1 ml of various virus 
dilutions using spin infection (300 g, 2h at 32°C) in the presence of 8 µg/ml 
polybrene (Hexadimethrine-Bromide, Sigma-Aldrich). After 4 h at 37°C the virus 
dilution was replaced with NIH3T3 medium and cells were incubated for two 
more days. Then cells were harvested with Trypsin/EDTA and total genomic 
DNA was isolated for qPCR analysis (see 4.2.2.8).  
 
4.2.1.3 CFSE staining 
Labeling of cells with CFSE (carboxyfluorescein-diacetate-succinimidylester, life 
technologies) allows tracking of cell division both in vitro and in vivo. CFSE 
diffuses into the cell, where it binds to amino groups of proteins. By cleavage with 
intracellular esterases, CFSE becomes a fluorescent dye. After each cell division 
the amount of dye is divided equally between the daughter cells. As a 
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consequence, fluorescence intensity is reduced by 50%, leading to a characteristic 
peak pattern, in which the number of cell divisions can easily be identified. For 
CFSE labeling, a single cell suspension was resuspended in prewarmed PBS 
containing 0.1% FBS and 5 µM CFSE is added while vortexing to ensure 
homogeneous staining. Cells are incubated for 10 min at 37°C and protected from 
light. The reaction is stopped by adding an equal volume of pure FBS. The cells 
are washed two times with PBS and resuspended in the desired amount of PBS or 
culture medium. 
 
4.2.1.4 Determination of cell numbers 
To determine the cell number of primary cells a Coulter counter Z2 instrument 
(Beckman Coulter) was used. Cell count and size is measured by the change of 
electrical resistance that a cell causes by passing through a small hole in an 
electrode. For analysis 10 µl of cell suspension was diluted in 10 ml conductive 
solution (Isoton II, Beckman Coulter) and 2 drops of a lytic reagent (ZAP-
OGLOBIN II, Beckman Coulter) were added to remove residual erythrocytes. 
For cell counting of cell lines like 293FT and NIH3T3 a Neubauer counting 
chamber was used. 10 µl cell suspension were mixed with 90 µl Trypan blue, 
which stains dead cells. Only live cells were counted and the actual cell number 
(unit 106/ml) was calculated by division of the resulting number by 10. Total cell 
numbers of a certain population within an organ were calculated by multiplying 
the percentage of the population of interest with the cell number of the respective 
organ and dividing it by 100. 
 
4.2.1.5 Flow cytometry - Fluorescence-Activated Cell Sorting 
(FACS) 
In flow cytometry various characteristics of single cells such as size, granularity 
and molecular marker expression can be detected. Cells are stained with 
fluorochrome-coupled antibodies against surface or intracellular antigens. In a 
fluid stream cells pass a laser beam and several detectors. The resulting 
information is collected and can be used for identification of distinct cell 
populations within a heterogeneous mixture of cells.  
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An advanced development of classical flow cytometry is cell sorting. On a 
specialized instrument (FACSAria, BD) the population of interest can be defined 
by the user and is then collected by electrostatic droplet deflection. 
In a 5 ml reaction tube 50 µl of a single cell suspension (1-5x106 cells) were mixed 
with 50 µl of a 2x concentrated antibody solution at an appropriate dilution 
(antibodies were titrated before use). The tubes were incubated in the dark at 4°C 
for 20 min. The cells were then washed with 2-3 ml FACS buffer to remove excess 
of unbound antibodies (300g, 4°C). If biotinylated antibodies were used, a second 
staining step with fluorochrome-conjugated streptavidin followed. For 
intracellular cytokine staining splenocytes (10x106) were restimulated for 4 h in 1 
ml with 2 µg SIINFEKL or SSIEFARL peptide in the presence of 2 µl GolgiStop 
(BD), which blocks protein secretion. Intracellular staining was performed using 
the Cytofix/Cytoperm kit (BD) according to the manufacturer’s protocol. MHC 
tetramers were used according to the manufacturer’s protocol (ProImmune). 
 
Prior to acquisition all samples were filtered (41 µm mesh; Reichelt 
Chemietechnik, Heidelberg, Germany) to remove cell aggregates. Data were 
aquired on a FACSCalibur with two lasers (488 and 633 nm) or on a FACSCanto II 
instrument with three lasers (488, 633 and 405 nm) and analyzed with FlowJo 
software (TreeStar, Ashland, OR, USA). 
 
4.2.1.6 Generation of bone marrow chimeras 
Recipient mice were lethally irradiated with two separate doses (2x 550 rad) using 
a Cesium source (Gammacell 40, AECL, Mississauga, Canada) and supplied with 
neomycin (1.2 g/l, Sigma-Aldrich) containing drinking water for five weeks. 
Chimeras were analyzed 8-10 weeks after bone marrow transfer. For most of the 
experiments HSCs that had been lentivirally transduced were transferred 
intravenously. In some cases untreated bone marrow was used directly after 
isolation. 
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4.2.1.7 Harvesting of blood and organs from mice  
Harvesting peripheral blood  
Before blood extraction, mice were placed under an infrared lamp for few minutes 
to generate vasodilatation. Mice were put in a trap and a small cut was made in 
the tail vain with a scalpel blade. In an eppendorf tube 3-5 drops (100-150 µl) of 
blood were collected and mixed with 50 µl heparin-sodium (25000 I.E./5 ml, 
Ratiopharm, Ulm, Germany).  
 
Harvesting organs and preparation of single cell suspensions  
Mice were sacrificed by cervical dislocation, fixed with needles on a styrofoam 
pad, disinfected with 70% ethanol and cut open. Thymus, lymph nodes and spleen 
were harvested with fine tweezers and kept on ice in RPMI medium. For 
generation of single cell suspensions organs were placed in a petri dish (Ø 5 cm) 
between two 150 µm meshes (Reichelt Chemietechnik) and mashed with a 1 ml 
syringe plunger (Omnifix, Braun, Melsungen, Germany). For optimal recovery of 
dendritic cells (DC) organs were treated by enzymatic digestion: injection with a 
solution containing Liberase CI (0.42 mg/ml) and DNase I (0.2 mg/ml, both from 
Roche) and incubation for 25 min at 37°C, followed by mechanical dispersion 
using a cell strainer (100 µm, BD).  
For preparation of bone marrow the hind legs were removed. The bones were 
cleaned from muscles, separated into tibia and femur and quickly disinfected with 
70% ethanol. The terminal parts of the bones were cut open and the bone marrow 
was flushed out with needle and syringe. For large-scale isolation bones were 
placed in medium and carefully fragmented with a mortar and pestle. Bone 
marrow was harvested from the supernatant and filtered through a cell strainer. 
 
Erythrocyte lysis 
Erythrocytes from peripheral blood were lyzed using Pharm Lyse reagent (BD) 
according to the manufacturer’s instructions. 
Cell pellets from organs were resuspended in 4 ml ACK buffer and left for 5 min 
at RT. Afterwards 10 ml FACS buffer was added, the cells were centrifuged (5 min 
at 4°C, 300 g) and resuspended in culture medium or FACS buffer. A more gentle 
treatment (Mouse Erythrocyte Lysing Kit, R&D Systems) was used according to 
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the manufacturer’s instructions for bone marrow preparations or if cells were used 
for intracellular cytokine staining. 
After erythrocyte lysis cell pellets were resuspended in the desired amount of 
medium or FACS buffer.  
 
4.2.1.8 Histology 
Organs were embedded in O.C.T. compound (Sakura Finetek, Zoeterwoude, The 
Netherlands), snap frozen and cut in 5 µm sections on a cryostat instrument (Jung 
Frigocut 2800 E, Leica Microsystems, Wetzlar, Germany). Sections were air-dried 
for at least 1 h, fixed with acetone (-20°C for 10 min) and stained by standard 
protocol with anti-CD8-PE (clone 53-6.7, eBioscience). Analysis was performed on 
a BX41 microscope equipped with a F-view II camera and cell^F software (all from 
Olympus, Hamburg, Germany).  
 
4.2.1.9 Immunizations 
Virus stocks were thawed on ice and treated with ultrasound for 10 seconds 
(Ultrason E, Greiner, Frickenhausen, Germany). Virus concentration was adjusted 
with PBS and 4x106 pfu of rHSV-1 expressing OVA (HSV-OVA) was injected i.v. 
per mouse. 
 
4.2.1.10 Magnetic cell sorting (MACS)  
Magnetic cell sorting (MACS, Miltenyi Biotec) is a technique that allows isolation 
of various cell subpopulations based on their expression of different antigens on 
the cell surface. In general there are two possible methods for cell sorting: labeling 
the population of interest (positive selection) or labeling all other cells (negative 
selection). The MACS principle is based on the use of monoclonal antibodies that 
are conjugated to superparamagnetic microbeads. After labeling, the cells are 
applied to a column that is placed in a magnetic field of a MACS separator. There 
are different columns for different purposes and for different numbers of cells. 
Labeled cells (the positive fraction) are retained inside the column by the magnetic 
field, while the unlabeled ones (the negative fraction) pass through. The column is 
washed three times with MACS buffer to remove excess unlabeled cells. After 
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removal of the column from the magnetic field, the cells retained in column can be 
eluted. MACS separation was applied to purify dendritic cells (CD11c microbeads, 
positive selection) and CD8+ T cells (CD8+ T cell Isolation Kit, negative selection) 
from cells isolated from spleen, lymph nodes and thymus. For some experiments, 
bone marrow preparations were depleted of CD8 T cells using CD8 microbeads. 
All procedures were performed according to the manufacturer’s instructions. 
 
4.2.1.11 Production of lentiviral vectors 
For virus production 293FT cells (Invitrogen) were transiently transfected using 
the standard calcium phosphate precipitation method. 293FT cells were plated 14-
18 hours before transfection (5.5x106 cell per 100 mm cell culture plate) and kept at 
37°C and 10% CO2. Throughout the whole virus production 293FT medium 
without geneticin was used to avoid additional cellular stress. For the transfection 
procedure 20 µg lentiviral vector, 15 µg pCMVΔR8.2 and 10 µg pMD2G (coding 
for VSV-G) were mixed with 100 µl CaCl2 and sufficient water for a total volume 
of 1 ml. Under vortexing 1 ml 2xHBS was added. This solution was added 
dropwise to the plates, which were incubated for 3-5 hours. Afterwards cells were 
washed with pre-warmed PBS and fresh 293FT medium (10 ml) was added. The 
handling of the plates was performed very carefully to avoid detachment of the 
cell monolayer. Supernatants were harvested and filtered (0.45 µm filter, Nalgene 
Nunc) on three consecutive days starting one day after transfection. All 
supernatants were pooled and stored at 4°C until the last harvest, when they were 
either directly partitioned into aliquots or concentrated using Centricon filter 
devices (Plus-80, Millipore, Billerica, MA, USA) according to the manufacturer’s 
instructions. This method of ultrafiltration is based on the following principle: 
centrifugal force drives a solution against a membrane with a particular cutoff 
(100kDa). The membrane traps high-molecular substances like viruses, whereas 
smaller molecules pass through. Thereby the lentiviral supernatant could be 
highly concentrated (up to 100-fold) without loss of virus. Aliquots were snap-
frozen in liquid nitrogen and stored at -80°C until use.  
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4.2.2 Molecular biology methods  
4.2.2.1 Agarose gel electrophoresis 
This technique was used to separate DNA fragments according to their length. By 
comparison to a 100bp or 1kb ladder (New England Biolabs (NEB), Ipswich, MA, 
USA) the actual size of the fragments was estimated. Before gel loading the DNA 
samples were mixed with gel loading dye (10% glycerol, xylene cyanol FF). 
Separation was carried out by application of constant voltage (80V) to an 
electrophoresis chamber containing conductive buffer (TAE). Depending on the 
size of the DNA fragment of interest different amounts of agarose were used (0.5-
2% w/v). DNA was visualized by addition of ethidium bromide to the gel (0.5 
µg/ml) and subsequent examination under UV light (312 nm, Intas, Goettingen, 
Germany). For cloning, DNA fragments were excised with a clean scalpel and 
then isolated from the gel (see 4.2.2.4).   
 
4.2.2.2  Cleavage of DNA with restriction enzymes 
Restrictions enzymes were used to characterize and identify DNA fragments, as 
well as to prepare DNA fragments for cloning. All restrictions enzymes were 
purchased from NEB and were used according to the manufacturer’s instructions. 
 
4.2.2.3  Culture of bacteria 
Transformed bacteria were cultured in reaction tubes with LB medium (Roth, 
Karlsruhe, Germany) in a shaker (Infors, Bottmingen, Switzerland) at 37°C 
overnight. Since all plasmids and vectors contained an ampicillin resistance gene, 
100 µg/ml of the antibiotic was added to the LB medium for selection of 
transformed bacteria. For generation of single colonies LB-agar plates (7.5 g 
agar/500 ml LB medium, containing 100 µg/ml ampicillin) were placed in an 
incubator at 37°C overnight. 
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4.2.2.4 DNA and RNA isolation and purification 
The following kits were used according to the manufacturer’s protocols. During 
RNA isolation residual amounts of DNA were removed by on-column DNase I 
treatment. All kits were purchased from Qiagen (Hilden, Germany): 
 
Purification of DNA fragments from agarose gel  QIAquick Gel Extraction Kit 
 
Isolation of plasmid DNA (small-scale)   QIAprep Spin Miniprep Kit 
       
Isolation of plasmid DNA (large-scale)   QIAfilter Plasmid Maxi Kit 
 
Isolation of genomic DNA     DNeasy Blood & Tissue Kit 
 
Isolation of total RNA      RNeasy Mini Kit 
 
RNeasy Micro Kit (for small 
cell numbers)  
4.2.2.5 Ligation of DNA fragments 
Ligation reactions were composed of 50 ng vector DNA and a threefold molar 
excess of insert DNA in ligase buffer and 400U T4 DNALigase (NEB) in a final 
volume of 20 µl. The reaction was performed at RT for 1 h or at 4°C overnight. For 
transformation into competent bacteria 5 µl of the ligation reaction was used.  
 
4.2.2.6 Measurement of nucleic acid concentration  
Nucleic acid concentrations were determined by UV absorbance measurement at 
260 nm. For this purpose samples were either used undiluted and measured 
directly with a NanoDrop instrument (Thermo Fisher Scientific, Waltham, MA, 
USA) or diluted in plastic cuvettes (Brand, Wertheim, Germany) and measured 
with a Biophotometer (Eppendorf, Hamburg, Germany). The 260/280 ratio is an 
indicator for nucleic acid purity: values between 1.8-2 are desirable, as this means 
a low amount of protein contamination.  
Titration of lentiviral vectors was performed by qPCR (see 4.2.2.8) using absolute 
quantification. Therefore a standard curve was prepared with serial dilutions of 
plasmid DNA, where concentrations were very low and high accuracy was 
necessary. Therefore a Qubit fluorometer and the dsDNA HS Assay Kit (both from 
Invitrogen) were used according to the manufacturer’s protocols. This method 
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involves the addition of a DNA binding fluorescent dye, which increases 
sensitivity. 
 
4.2.2.7  Polymerase chain reaction (PCR) 
Using this method, a particular DNA sequence is amplified from a small amount 
of template DNA. For this process specific primers that flank the region of interest 
are used. For subsequent molecular cloning of the PCR product restriction sites 
can be incorporated terminally in the primer sequence. Thermal cycles alternate 
that allow DNA denaturation, primer annealing and DNA synthesis. For PCR the 
Platinum Taq High Fidelity DNA polymerase (Invitrogen) was used to avoid 
undesired mutations during the reaction. 
 
Reaction composition: 
 
5-50 ng plasmid DNA 
0.4 µM primer for  
0.4 µM primer rev 
1 x High Fidelity PCR buffer 
200 µM dNTP mix  
2 mM MgSO4 
1 U Platinum Taq High Fidelity DNA polymerase  
H2O ad 50 µl 
  
The melting temperature (TM) of primers was calculated with the following 
formula: TM = [(G+C) x 4°C] + [(A+T) x 2°C] 
Depending on the TM the annealing temperature (TA) of primers in the PCR 
reaction was calculated: 
TA = TM-5°C 
 
PCR reactions were performed with a T3 Thermocycler (Biometra) using the 
following program: 
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Step 1: 94°C 5 min 
Step 2: 94°C 30 sec 
Step 3:  55°C 30 sec   (TA can vary dependent on TM) 
Step 4:  68°C 1 min per kb  back to step 2 (30 cycles) 
Step 5:  68°C 10 min 
Step 6:  4°C ∞  
 
PCR products were analyzed on an agarose gel and excised, if used for cloning.  
 
4.2.2.8 Quantitative PCR (qPCR) 
Quantitative PCR is used to determine the exact amount of a particular DNA 
sequence within a sample. There are two different methods to detect the amount 
of PCR product during the PCR reaction, namely in “real time”: SYBR green is a 
fluorescent dye that intercalates with any double stranded DNA, whereas TaqMan 
probes bind specific sequences. These probes are oligonucleotides that are labeled 
with fluorescent dyes, which only give a signal when the probe is bound to DNA. 
The cycle number (crossing point, CP) when fluorescence intensity exceeds a 
certain threshold is correlated with the initial amount of the relevant template 
DNA. 
 
Detection via SYBR green 
Two days after lentiviral transduction genomic DNA from NIH3T3 cells was 
isolated and eluted in 150 µl water. DNA was analyzed in duplicates by 
quantitative PCR (Lightcycler FastStart DNA MasterPLUS SYBR Green I Kit, Roche) 
on a Lightcycler Carousel-based system (Roche). Viral integration (forward 5’-
TGAAAGCGAAAGGGAAACCA-3’ and reverse 5’-CCGTGCGCGCTTCAG-3’) 
was investigated per cell (BDNF forward 5’-ACGACATCACTGGCTGACAC-3’ 
and BDNF reverse 5’-CATAGACATGTTTGCGGCATC-3’). Standard curves were 
generated with 100-fold serial dilutions of plasmids containing the relevant 
template DNA (FUGW or pBS-BDNF) and absolute quantification was used to 
calculate the viral titers. 
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Reaction composition: 
 
2 µl DNA 
0.75 mM primer for (1 mM for Bdnf) 
0.2   mM primer rev (1 mM for Bdnf) 
1x Master SYBR Green I mix 
H2O ad 20 µl  
 
The following PCR program was used: 
 
Step 1: 95°C 10 min 
Step 2: 95°C 10 sec 
Step 3:  60°C   5 sec    
Step 4:  72°C 10 sec   back to step 2 (40 cycles) 
 
Melting curve acquisition was performed as suggested by the manufacturer’s 
protocol.   
The final calculation of the virus titer was done using the following formulas: 
 
  number of NIH3T3 cells x number of virus copies per genome 
Virus titer =  
 (TU/ml)    volume of virus (ml) 
 
     volume of virus (ml) x virus titer (TU/ml) 
MOI           = 
               number of cells 
 
Detection with TaqMan probes 
Equal amounts of RNA were used for cDNA synthesis with the SuperScript III 
First-Strand Synthesis SuperMix for qRT-PCR (Invitrogen). The TaqMan assay 
was performed with the LightCycler TaqMan Master Kit (Roche) and the 
Universal ProbeLibrary Set mouse (Roche) according to the manufacturer’s 
instructions on a CFX96 Real Time System (BIO-RAD) using the primers and 
probes listed in Table 3. Expression levels were normalized to Ubiquitin C or 
CD11c and relative quantification was calculated using the ΔΔCT-method (78). 
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Table 3  Primers and probes for quantitative TaqMan PCR. 
Gene Forward Primer Reverse Primer Probe # 
UBC 5’-GAGTTCCGTCTGCTGT GTGA-3’ 
5’-TCACAAAGATCTGCAT 
CGTCA-3’ 77 
CD11c 5’-CCAGTTGGAGCTTCCA GTAAA-3’ 
5’-CCTTTTCTGAGGTTGA 
GAAGTTAAG-3’ 46 
DC-
STAMP 
5’-GTATCGGCTCATCTCC 
TCCA-3’ 
5’-ACTCCTTGGGTTCCTT 
GCTT-3’ 11 
PPEF2 5’-TTCTGTCACAACCGCA AGG-3’ 
5’-TCTGTTGCTGCCAACT 
TCAT-3’ 16 
PFTK1 5’-ATGGACAAGCACCCT GGA-3’ 
5’-CGCAGCAGCTGAAAT 
AAAAA-3’ 58 
OVA 5’- GCTATGGGCATTACT GACGTG-3’ 
5’-TGCTGAGGAGATGCC 
AGAC-3’ 41 
 
4.2.2.9 Production of chemo-competent bacteria  
A single colony of Escherichia coli (E. coli) Stbl3 (Invitrogen) was inoculated in LB 
medium without ampicillin and incubated overnight. The next day, 1 ml of this 
culture was diluted in 99 ml of LB medium containing 10 mM MgCl2 and 
incubated at 37°C in a shaker until an OD600 of 0.4-0.6 was reached. The bacterial 
culture was immediately cooled on ice for 10 min, followed by centrifugation at 
3000g, 4ºC for 25 min. The pellet was resuspended in 40 ml pre-cooled RFI 
medium and left on ice for 15 min. After centrifugation, the pellet was 
resuspended in 4 ml RFII medium and incubated on ice for further 15 min. 
Aliquots of 100 µl were prepared on dry ice and stored at – 80°C. 
The E. coli Stbl3 strain is specifically designed for cloning of lentiviral vectors. 
Presence of long terminal repeats (LTRs) makes these vectors unstable, because it 
results in undesired homologous recombination. The E. coli Stbl3 strain is deficient 
for the relevant recombinase. 
 
4.2.2.10 Transformation of chemo-competent bacteria 
Competent bacteria (100 µl) were thawed on ice for 5 min. Plasmid DNA (1 µl 
intact plasmid, 5 µl ligated plasmid) was added to the cells, carefully mixed and 
incubated on ice for 30 min. A heat shock was performed at 42 ºC for 45 seconds 
and the vial was placed directly back on ice. LB medium (500 µl) was added and 
the cells were incubated for 1 h at 37 ºC with shaking. The cells were then plated 
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on pre-warmed LB agar plates containing ampicillin and incubated overnight at 37 
ºC. For transformation of an intact highly concentrated plasmid 100 µl of bacterial 
suspension was plated, whereas for a ligated plasmid all cells were used. 
 
4.2.3 Computational promoter analysis 
Sequence information of promoter regions was retrieved from ElDorado software 
(Genomatix, Munich, Germany). In this program, a promoter is generally assumed 
(without further experimental information to integrate) to be located 500bp 
upstream and 100bp downstream of the transcriptional start site (TSS), but for 
some analyzes we enlarged the regions further upstream to -1400 or -1900bp. In 
the figures, the location of TSSs is depicted according to ElDorado, which uses 
information derived from CAGE tags and individual cDNAs. For definition of 
TFBSs the Matrix family library (Version 8.2, Genomatix) was used. To avoid 
redundancy, various information about binding sequences is used to calculate a 
weight matrix. Based on similarities in binding pattern and functionality the 
matrices are clustered into families (79). The version of the vertebrate library we 
used contains 727 matrices grouped in 170 families. Using Frameworker software 
(Genomatix) different promoter regions were compared and screened for a set of 
TFBSs with a defined order and orientation, a so-called “framework”. Default 
settings were used except for the maximum distance variance between two 
elements, which was increased from 10 to 20bp (CD11c mouse and human with 
DC-STAMP mouse) or 30bp (CD11c rat). In addition, the search was sometimes 
limited to the respective TF families (CD11c rat and DC-STAMP rat). The 
CD11c/DC-STAMP promoter model was refined by adjusting the distance ranges 
to the values from the CD11c rat search result. Subsequently, the model was used 
to perform a mouse promoter database search with default settings 
(ModelInspector, Genomatix).  
We also employed another platform, the “immunological genome project” 
(www.immgen.org, (80)), where microarray data of various primary cell types are 
compared and gene constellations are calculated. 
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4.2.4 Statistical analysis 
P-values were calculated with Student’s t test using PRISM software (GraphPad 
software, La Jolla, CA, USA) and are defined as: ***: p<0.001, **: p=0.001 to 0.01,           
*: p=0.01 to 0.05. Error bars represent standard deviations (SD). All experiments 
had a sample number of at least three mice per group, unless otherwise stated. 
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5 RESULTS 
5.1 Transcriptional targeting of antigen to DCs by 
the DC-STAMP promoter induces tolerance in 
vivo 
A fragment of the mouse DC-STAMP promoter (1704bp, -1565bp to +131bp) was 
analyzed for tissue specificity in order to transcriptionally target DCs. Therefore a 
lentiviral vector was used, in which the promoter region drives eGFP as reporter 
gene (Fig. 5a). Using this vector, bone marrow chimeras were generated by 
transduction of hematopoietic stem cells (HSC) and subsequent injection into 
lethally irradiated recipients. Analysis of GFP expression by flow cytometry in 
various cell types demonstrated that the DC-STAMP promoter (pDC-STAMP) 
fragment was only active in DCs but not in other cell types from spleen, thymus 
and lymph nodes (Fig. 5b and (76)). 
 
 
 
Figure 5 The pDC-STAMP1.7kb drives expression selectively in DCs.  
(a) Schematic representation of the lentiviral-based SIN-vector containing a fragment of the mouse 
DC-STAMP promoter (1704bp) to control expression of eGFP (enhanced Green Fluorescent 
Protein). CMV, cytomegalovirus; Ψ, packaging signal; SIN, self-inactivating; LTR, long terminal 
repeat; WPRE, woodchuck hepatitis virus post-transcriptional regulatory element; ΔU3, deletion in 
the U3 region. (b) Promoter activity of the mouse DC-STAMP promoter in vivo as measured by 
flow cytometry. Spleen cells from bone-marrow chimeras generated with HSCs transduced with 
the DC-STAMP-GFP lentivirus were analyzed for GFP expression. The different cell types were 
identified based on the expression of the indicated markers. Overlays were generated after gating 
on the relevant population using cells from C57BL/6 mice as negative controls. Data shown are 
representative of two independently performed experiments with 4-5 mice per group. 
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As this strategy represents a novel method to deliver transgenes specifically to 
DCs in vivo without changing their phenotype, it allowed us to address the 
question, if DCs could induce tolerance in this system. We chose a membrane-
bound form of ovalbumin (OVA) as a model antigen, which was expressed under 
the control of pDC-STAMP (Fig. 6a).   
 
 
 
Figure 6 OVA expression in DCs induces central and peripheral tolerance of OT-I T cells. 
(a) Schematic representation of the DC-STAMP-OVA lentiviral vector. A fusion of ovalbumin to 
the transmembrane part of the transferrin receptor (tfrOVA) is controlled by the 1.7kb fragment of 
the mouse DC-STAMP promoter. From here on this vector is called DC-STAMP-OVA. (b) 
Experimental setup for generation of BM-chimeras. Bone marrow HSCs from OT-I mice were 
depleted of CD8 T cells and transduced with DC-STAMP-OVA or control lentivirus. Lethally 
irradiated B6 hosts were reconstituted with the respective HSCs and analyzed after 8 weeks by 
flow cytometry. (c) Analysis of OVA expression in CD11c-positive and -negative cells from DC-
STAMP-OVA and control virus chimeras. From thymus and spleen, cell fractions were isolated by 
magnetic bead sorting and RNA was prepared. RT-PCR analysis identified a 317bp fragment for 
trOVA and a 302bp fragment for β-actin as control. (d) Flow cytometric analysis of thymocytes. 
OT-I T cells were identified according to expression of CD8, TCRVα2 and TCRVβ5 as indicated by 
gates and quadrants. Total numbers of OT-I T cells in the respective chimeras were determined (**, 
p=0.004). (e) Frequencies of splenic OT-I T cells were determined by flow cytometry. Total 
numbers of OT-I T cells from spleens of both types of chimeras were compared (***, p=0.0002). 
   
Chimeras were generated using HSCs from OT-I transgenic mice, which express 
an OVA-specific TCR on CD8 T cells (Fig. 6b). Before transfer, those HSCs were 
either transduced with DC-STAMP-OVA or control lentivirus. As a result, OT-I T 
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cell development could be monitored in the absence or presence of OVA-
expressing DCs, which were found both in thymus and spleen (Fig. 6c). DC-
specific expression of OVA induced central tolerance of OT-I T cells, as seen by 
reduced frequencies and total numbers of thymic transgenic T cells in comparison 
to control chimeras (Fig. 6d). In spleen, OT-I T cell numbers were even more 
drastically reduced, indicating peripheral tolerance had been induced (Fig. 6e). It 
is important to note that transgenic OVA expression was detected in BM-chimeras 
even after ten months (data not shown).  
 
Taken together, the DC-STAMP lentivirus allows transcriptional targeting of Ag 
specifically to DCs. In this system, DC-specific expression of Ag induces central 
and peripheral tolerance, which is Ag-specific and long lasting. The results 
described in this section have been recently published (76). 
 
In the course of these experiments we made an interesting observation: a low 
number of mature OT-I T cells, which is usually present in the bone marrow HSCs 
of OT-I donor mice, had an inhibiting effect on central deletion of developing OT-I 
T cells, which was typically induced in DC-STAMP-OVA chimeras. As a 
consequence, we depleted the HSCs of OT-I donor mice of CD8 T cells before use 
and decided to further investigate the potential role of mature OT-I T cells in the 
thymus (see 5.2). 
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5.2 Peripheral T cells re-enter the thymus and 
interfere with negative selection in vivo 
5.2.1 Homeostatically expanding activated CD8 T cells re-
enter thymus and pancreas 
To analyze the potential functions of thymus homing mature T cells we employed 
one of the best-studied autoimmune mouse models, the RIP-mOVA mouse, which 
expresses the membrane bound form of chicken OVA in pancreatic β-cells as well 
as in thymic mTECs (14). These mice were lethally irradiated and reconstituted 
with bone marrow (BM) from syngeneic OT-I mice, which either contained or was 
depleted of mature CD8 OT-I T cells (Fig. 7a). When OT-I T cells were depleted 
from OT-I-BM (ΔCD8) before reconstitution (Fig. 7a), recipient chimeras showed 
no signs of diabetes (Fig. 7b). In contrast, chimeras receiving non-depleted BM 
developed lethal diabetes within 7 days (Fig. 7b), which was caused by OT-I T 
cells massively infiltrating the pancreas (Fig. 7c, d). In the same mice, we also 
found substantial numbers of OT-I T cells in the spleen (Fig. 7d, e). Notably, there 
were more OT-I T cells in the pancreas (Fig. 7h) and those cells displayed a much 
higher activation status (CD44highLy6Chigh, Fig. 7e) compared to the splenic 
counterparts. This shows that these highly activated effector cells tend to 
accumulate in their target organ, the pancreas, where they encounter their cognate 
antigen OVA.  
At day 8 after irradiation the thymus is only starting to be reconstituted and 
contains very few cells, mainly CD4 CD8 double negative T cells. As expected 
there were nearly no CD4 or CD8 single positive (SP) T cells in the thymus of 
ΔCD8 chimeras (Fig. 7f). In the undepleted chimeras, however, half of the cells 
were CD8 SP T cells and of those the vast majority expressed the OVA-specific 
transgenic TCR (Fig. 7f). The fact that those thymic OT-I cells express markers of 
mature thymocytes (CD24lo Qa-2high, Fig. 7g), which could not have developed in 
this short period, argues that these cells have re-entered the thymus from the 
periphery.  
 
To test if this re-migration is Ag-dependent and to characterize those cells in more 
detail, we transferred CFSE-labeled OT-I T cells together with normal B6 BM into 
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lethally irradiated B6 mice. The migratory behavior of adoptively transferred T 
cells was investigated in the absence of antigen 5 or 11 days after transfer (Fig. 8a). 
Already at day 5 after transfer re-migrated OT-I T cells were found in the thymus, 
although numbers were relatively low (Fig. 8b). 
 
 
 
Figure 7 OT-I T cells induce diabetes in lymphopenic RIPmOVA mice.  
(a) Thy1.1+ OT-I bone marrow (BM) was transferred either undepleted or after depletion of CD8 T 
cells (ΔCD8) into lethally irradiated RIPmOVA mice. (b) Mice were monitored for onset of diabetes 
and sacrificed 8 days after BM-transfer. (c) Immunofluorescence staining of pancreatic sections for 
CD8 (magnification 10x). Frequency (d) and surface phenotype (e) of donor-derived Thy1.1+ CD8 T 
cells in spleen and pancreas. (f) Flow cytometric analysis of Thy1.1+ donor-derived cells in the 
thymus. The frequency of CD8+ SP T cells and the percentage of TCR Vα2+ and Vβ5.1/5.2+ cells 
among them is indicated. (g) Developmental status of OT-I T cells in the thymus. (h) Total cell 
numbers of Thy1.1+ OT-I T cells in the indicated organs. Data are representative of three 
independent experiments with similar results (n=3-4 mice per group). 
 
The number of cells re-entering the thymus increased over time, approximately 
200-fold from day 5 to 11. The mature OT-I T cells also repopulated other organs, 
including the spleen, lymph nodes and pancreas. However, there was an obvious 
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difference in cell quality at day 11: re-migrated cells in the thymus had undergone 
the most divisions (CFSElo) and were highly activated (CD62Llo) as compared to 
cells in the spleen and lymph nodes (Fig. 8c). Pancreatic cells showed an 
intermediate phenotype. In keeping with a previous report from allogeneic 
settings (81), our data show that homeostatic proliferation generates T cells that 
are able to enter the thymus also independently of cognate antigen.  
 
 
 
Figure 8 Most activated OT-I T cells can enter the thymus.  
(a) Lethally irradiated B6 mice were reconstituted with syngeneic BM (3x106) together with CFSE 
labelled Ly5.1+ OT-I T cells (6.5x106) and analyzed at day 5 and 11 post transfer. (b) Total cell 
number (log scale) of adoptively transferred OT-I T cells in thymus, spleen and pancreas at day 5 
(grey bar) and day 11 (black bar). (c) CFSE profile and CD62L expression of OT-I T cells in the 
indicated organs at day 11. OT-I T cells were identified based on the expression of CD8 and the 
congenic marker (Ly5.1). Data are representative of two independent experiments with similar 
outcomes (n=3 per group). 
 
5.2.2 Thymus re-entry of peripheral T cells leads to Ag-
specific removal of thymic APCs and deficient 
negative selection 
We next wondered if these highly activated re-entered T cells display effector 
functions within the thymic microenvironment. To explore this we employed the 
lentiviral transduction system described above (see 5.1). Lentiviral transduction of 
BM HSCs with virus carrying the DC-STAMP-promoter allows specific 
transcriptional targeting of transgenes to DCs for induction of central and 
peripheral tolerance (76). This model offered the possibility to directly address the 
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question, if mature CD8 T cells from the periphery are able to interfere with 
thymic deletion of T cells, which recognize a defined antigen (OVA) specifically 
expressed by DCs.  
 
 
Figure 9 Adoptively transferred OT-I T cells disturb DC-mediated negative selection of 
BM-derived T cells.  
(a) Thy1.1+ OT-I BM HSCs were CD8 T cell depleted (ΔCD8) and transduced with control lentivirus 
or lentivirus encoding ovalbumin (OVA) under control of the DC-STAMP promoter (DC-STAMP-
OVA). The DC-STAMP-OVA lentivirus treated BM was injected into irradiated B6 mice either 
alone or together with 5x104 Ly5.1+ OT-I T cells. The presence of these cells is demonstrated in 
representative flow cytometric analyses of thymus and spleen (right) after gating on CD8 T cells. 
(b) Flow cytometric analysis of thymocytes after gating on donor specific (Thy1.1) cells (not 
shown). Expression of OT-I TCR Vα2 and Vβ5.1/5.2 on CD8 SP cells identifies them as BM-derived 
OT-I T cells. (c) Total cell number of BM-derived OT-I T cells in the thymus. (d) RNA from thymic 
cells was analyzed by quantitative PCR. In this bar graph, one bar represents one individual mouse 
and expression of OVA is shown relative to CD11c. Results are representative of three independent 
experiments with 3-4 mice per group. 
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We generated bone marrow chimeras using CD8 T cell depleted BM from Thy1.1+ 
OT-I donors, which was transduced either with DC-STAMP-OVA or control 
lentivirus and injected into lethally irradiated hosts. The DC-STAMP-OVA treated 
BM was used either alone or mixed with low numbers of Ly5.1+ OT-I T cells 
isolated from lymph nodes, representing mature CD8 T cells (5x104, Fig. 9a). As 
such, their influence on negative selection could be investigated. The use of 
different congenic markers allowed tracking of the origin of OT-I T cells. We 
monitored the development of Thy1.1+ BM-derived “endogenous” OT-I T cells in 
thymi without OVA (control virus) or in the presence of their cognate antigen 
OVA on thymic DCs (DC-STAMP-OVA lentivirus, Fig. 9a). In the third group 
(DC-STAMP-OVA + Ly5.1+OT-I), thymic DCs expressing OVA could be potential 
targets for activated re-entering Ly5.1+ OT-I T cells. If back-migrated T cells indeed 
function to kill thymic OVA+ DCs, negative selection should be obstructed, 
thereby allowing endogenous Thy1.1+ OT-I T cells to develop. As expected, 
adoptively transferred Ly5.1+ OT-I T cells homeostatically expanded and were 
found in the thymus and spleen of chimeric mice (Fig. 9a, right). While the 
endogenous BM-derived Thy1.1+ OT-I T cells developed normally in chimeras 
generated with control lentivirus treated BM (i.e. in the absence of OVA-
expressing DCs), their frequencies (Fig. 9b) and total numbers (Fig. 9c) were 
diminished to background levels in DC-STAMP-OVA chimeras due to negative 
selection, as previously published (76).  
 In contrast, the presence of re-migrated OT-I T cells in DC-STAMP-OVA chimeras 
strongly interfered with negative selection, as observed by the development of the 
endogenous Thy1.1+ donor-derived OT-I T cell population at near normal 
frequencies (Fig. 9b, c). When OT-I T cells were transferred into control chimeras 
(Fig. 10a), they re-migrated to the thymus, but did not influence the development 
of endogenous OT-I thymocytes (Fig. 10b). This control experiment excludes the 
possibility that the mere presence of mature OT-I T cells boosts the development 
of endogenous OT-I T cells.  
 
In order to investigate, if OT-I T cell development was due to a lack of OVA 
expression in the thymus, we performed qPCR on thymic cells from the different 
groups. This analysis revealed that re-migrating Ly5.1+ OT-I T cells caused 
disappearance of OVA mRNA-expression, while OVA remained detectable in 
thymi of DC-STAMP-OVA treated chimeras (Fig. 9d). As we have previously 
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shown in DC-STAMP-OVA chimeras that thymic expression of OVA is confined 
to DCs (76), our data suggest that mature T cells expand homeostatically in 
lethally irradiated hosts and enter the thymus, where they eliminate thymic DCs. 
This allows endogenous thymocytes to develop in the absence of negative 
selection. 
 
 
 
Figure 10 Adoptively transferred OT-I T cells have no influence on the development of 
BM-derived OT-I cells in control chimeras 
(a) OT-I BM HSCs were CD8 T cell depleted and transduced with DC-STAMP-OVA or control 
lentivirus. In both groups BM was either injected alone or together with 5x104 mature OT-I T cells 
(Thy1.1) into lethally irradiated B6 recipients. (b) Total cell number of BM-derived OT-I T cells in 
thymus (left) and spleen (right) is displayed.  
 
As we have demonstrated before (Fig. 6e and (76)) that OVA expression in DCs 
leads to peripheral tolerance, we also analyzed splenocytes from the same mice as 
in Figure 9. In control chimeras, OT-I T cells were present at normal frequency 
(Fig. 11a) and numbers (Fig. 11b), but in DC-STAMP-OVA chimeras those few OT-
I T cells that left the thymus were even more reduced in the periphery.  
This residual cell population was characterized by surface markers associated 
with chronic infection or constant presence of antigen (82): upregulation of PD-1 
and downregulation of Ly6C (Fig. 11c). However, in the presence of adoptively 
transferred OT-I T cells (Ly5.1), endogenous OT-I T cells remained in the 
periphery, although not reaching normal levels (Fig. 11a, b), and displayed marker 
expression of naive T cells (Fig. 11c). QPCR analysis of splenocytes showed 
 
59 
reduced OVA expression if mature OT-I T cells had been adoptively transferred 
(Fig. 11d). These findings demonstrate that CD8 T cells can eliminate DCs in an 
Ag-dependent manner not only in lymph nodes (34) and tissues (33) but also in 
the spleen. 
 
 
 
Figure 11 Adoptively transferred OT-I T cells disturb DC-mediated peripheral tolerance of 
BM-derived T cells.  
Flow cytometric analysis of splenocytes from the same experiment as in Figure 9 (for experimental 
setup see Fig. 9a). Frequency (a) and total cell number (b) of BM-derived (Thy1.1) OT-I T cells in 
spleen. (c) Analysis of activation markers on BM-derived OT-I T cells from spleen. (d) Expression 
of OVA relative to CD11c in splenocytes. In this bar graph, one bar represents one individual 
mouse. Results are representative of one out of three independent experiments with 3-4 mice per 
group. 
 
As we have shown (76) that antigen expression in DCs also results in thymic 
depletion of CD4 T cells, we wanted to know if peripheral OT-I T cells would 
similarly interfere with negative selection of OT-II cells. OT-II BM was transduced 
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with control virus or DC-STAMP-OVA virus, which was either injected alone or 
together with mature OT-I T cells (Fig. 12a). In addition, we wanted to test 
whether the number of OT-I -“contaminants” could be decreased. Therefore, we 
transferred instead of 5x104 either 1x104 or 1x103 cells (Fig. 12a). OT-I T cells were 
indeed able to interfere with negative selection of OT-II cells. As few as 1x103 OT-I 
contaminants were sufficient to inhibit negative selection, allowing normal 
percentages of OT-II cells to develop (Fig. 12b, left). Moreover, also in the spleen 
equal percentages of OT-II cells were present in comparison to control chimeras 
(Fig. 12b, right). This indicates that also in this setting, regarding CD4 T cells, 
removal of Ag-expressing DCs in thymus and spleen by adoptively transferred 
OT-I T cells interferes with central and peripheral tolerance. 
 
 
 
Figure 12 Adoptively transferred OT-I T cells disturb DC-mediated negative selection of 
OT-II T cells.  
(a) OT-II BM HSCs were transduced with control lentivirus or DC-STAMP-OVA lentivirus. The 
DC-STAMP-OVA lentivirus treated BM was injected into irradiated B6 mice either alone or 
together with 1x104 or 1x103 Ly5.1+ OT-I T cells. (b) Percentage of OT-II T cells in thymus (left) and 
spleen (right). Data represent two independent experiments with 2-4 mice per group (*: p<0.05 and 
***: p<0.001). 
 
In addition to thymic DCs, mTECs are another key mediator of central tolerance 
induction. These cells efficiently express and present self-Ags, and might serve as 
an Ag-source for thymic DCs (83). In order to study whether mTECs could also be 
targets for mature re-entered thymic CD8 T cells, we employed RIP-mOVA mice, 
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in which the self-Ag OVA is expressed selectively in thymic mTECs (14). 
Following lethal irradiation of RIP-mOVA hosts, we adoptively transferred 
Thy1.1+ΔCD8-OT-I BM either alone or together with Ly5.1+OT-I T cells (Fig. 13a).  
 
 
 
Figure 13 Adoptively transferred OT-I T cells disturb mTEC-mediated negative selection 
of BM-derived T cells.  
(a) Thy1.1+ OT-I BM was depleted of CD8 T cells (ΔCD8) and injected into lethally irradiated 
RIPmOVA mice either alone or together with 5x104 Ly5.1+ OT-I T cells (ΔCD8+OT-I). Chimeras 
were analyzed at day 22 after transfer. Representative flow cytometric analysis of thymocytes after 
gating on CD8 SP thymocytes is shown (right). (b) Thymocytes were analyzed for CD4 and CD8 
expression by flow cytometry after gating on donor cells (Thy1.1). The frequency of OT-I TCR Vα2 
and Vβ5.1/5.2 positive cells was determined. (c) Percentage of BM-derived OT-I T cells in the 
thymus of ΔCD8→RIPmOVA (n=9) and ΔCD8+OT-I→RIPmOVA chimeras (n=7) were compared 
(***, p=0.0003). (D) Frequency of CD69hi and Thy1.1lo cells in the BM-derived OT-I population. Data 
are representative of two independent experiments with 4-9 mice per group.  
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This experiment is analogous to Figure 7, but in this case the OT-I contaminants 
were isolated separately and carried a congenic marker. As described before (Fig. 
7), the presence of mature OT-I cells in irradiated RIPmOVA mice resulted in the 
development of severe diabetes within one week. As this is too early to investigate 
thymic T cell development, we had to treat the diabetic mice with insulin, which 
enabled us to look at later time points (day 22).  
As previously shown, mTECs of RIP-mOVA mice express transgenic OVA (14) 
and therefore induce efficient negative selection. Consistently, only low numbers 
of BM-derived Thy1.1+CD8+ SP T cells expressing the transgenic OT-I TCR 
Vα2Vβ5 combination could be found in mice reconstituted with ΔCD8-BM (Fig. 
13b, c). These cells were CD69highThy1.1lo (Fig. 13d), showing a phenotype of recent 
activation, probably by Ag-recognition (84, 85). In contrast, development of 
endogenous Thy1.1+OT-I T cells was much more efficient in RIP-mOVA hosts that 
had also received mature peripheral Ly5.1+OT-I T cells (Fig. 13b, c). These BM-
derived OT-I T cells had a naive surface phenotype (CD69loThy1.1high) (Fig. 13d), 
suggesting development in absence of Ag. These results demonstrate that not only 
DCs, but also mTECs, are targets for re-entering CD8 T cells. 
 
5.2.3 Re-entered mature T cells induce development of self-
reactive endogenous T cells  
We next wanted to monitor if the observed inhibition of thymic negative selection 
is restricted to the development of transgenic T cells or would also occur in normal 
mice with polyclonal T cell repertoires. To this end we generated C57BL/6 
chimeras using C57BL/6-BM transduced with control or DC-STAMP-OVA 
lentivirus. The DC-STAMP-OVA treated BM was injected either alone or together 
with low numbers of Thy1.1+ OT-I T cells (Fig. 14a). As in this system the 
frequencies of Ag-specific T cells are too low to detect, thymic development could 
not be monitored. Therefore, we had to use an indirect approach, in which 
peripheral Ag-specific T cells were expanded by immunization and subsequently 
analyzed for functionality. Before immunization we removed the adoptively 
transferred Thy1.1+ OT-I T cells by injection of a Thy1.1-specific depleting 
antibody to avoid interference with the expansion of polyclonal T cells (Fig. 14b).  
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Figure 14 Adoptively transferred OT-I T cells disturb negative selection of a polyclonal 
CD8 T cell repertoire.  
(a) B6 BM HSCs were transduced with control lentivirus or DC-STAMP-OVA lentivirus. The DC-
STAMP-OVA lentivirus treated BM was injected into lethally irradiated B6 recipients either alone 
or together with 5x104 Thy1.1+ OT-I T cells. (b) After at least 8 weeks, the adoptively transferred 
OT-I T cells were removed by treatment with a depleting Thy1.1 antibody two days before 
immunization and remained undetectable throughout the course of the experiment. Shown are 
representative stainings of blood samples at the indicated time points. (c) Percentage of tetramer 
positive cells (H-2Kb-OVA and H-2Kb-gB) in the splenic CD8 T cell population seven days after 
immunization. Representative dot blots are shown and data from two independently performed 
experiments (n=2-3 per group) are pooled and statistically analyzed. (d) Spleen suspensions were 
stimulated in vitro with the OVA-peptide SIINFEKL or the gB-peptide SSIEFARL and analyzed 
after 5 h for surface expression of CD44 and production of IFNγ by intracellular staining. 
Representative flow cytometric data are shown after gating on the CD8 positive population. From 
one experiment, percentages of IFNγ producing cells among CD8 T cells are displayed (n=3 per 
group).  
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We then immunized mice with replication-deficient Herpes simplex virus (HSV) 
expressing recombinant OVA and monitored the induced CD8 T cell responses 
(Fig. 14c).  
As expected, all chimeras mounted efficient polyclonal CD8 T cell responses 
against the unrelated MHC class I Kb-restricted HSV-gB epitope SSIEFARL (Fig. 
14c, lower row). In contrast, while control chimeras also showed CD8 T cell 
responses to the Kb-restricted OVA-epitope SIINFEKL, DC-STAMP-OVA chimeras 
did not, as their T cell repertoire was devoid of OVA-specific cells due to 
lentivirus-mediated OVA-expression in thymic DCs leading to central tolerance 
(Fig. 14c, upper row; (76)). However, when adoptively transferred OT-I T cells 
were present and acted to remove OVA-expressing thymic DCs in DC-STAMP-
OVA chimeras, OVA-specific peripheral CD8 T cells were again detectable in 
peripheral organs by MHC-tetramers (Fig. 14c), which also showed effector 
functions by production of IFNγ (Fig. 14d).  
 
Taken together, these data indicate that the presence of mature CD8 T cells in a 
lymphopenic host disturbed common tolerance mechanisms and thereby induced 
the development of functional self-reactive CD8 T cells. As such, we could add 
another important function for re-entering T cells to the already proposed ones 
(61). 
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5.3 In vivo analysis of the mouse CD11c promoter: 
Identification of a Dendritic Cell-specific 
enhancer 
5.3.1 Comparative promoter analysis of CD11c and DC-
STAMP promoters across species identified conserved 
promoter structures 
The 5.5kb region upstream of the transcriptional start site of the mouse CD11c 
gene (86) and the 1.7kb fragment of the mouse DC-STAMP promoter (Fig. 5 and 
(76)) were successfully used to drive DC-specific gene expression. In addition, it 
has been shown that DC-STAMP parallels the expression of CD11c (87). To 
investigate if these two promoters share common features regarding 
transcriptional regulation, we decided to compare the two promoters across 
species using computational analysis.  
 
CD11c is an integrin αX, which forms a heterodimer with the integrin β2-chain 
(CD18). This complex is known to bind LPS, fibrinogen and the complement 
component iC3b and is therefore also called complement receptor 4 (CR4). It 
mediates cell adhesion by binding several adhesion molecules (ICAM-1, ICAM-2, 
VCAM-1). Considering these binding capacities, two roles have been proposed 
that can be functionally linked to DCs: antigen uptake and T cell activation (88, 
89). 
 
The dendritic cell-specific transmembrane protein (DC-STAMP) is preferentially 
expressed in DCs and localizes to the ER (87). It has been implicated in the 
differentiation of myeloid cells (90), the negative regulation of DC function (91) 
and also plays a role in osteoclast fusion (92). The currently known interaction 
partners for DC-STAMP are the ER-resident proteins OS9 (93) and LUMAN (94), a 
transcription factor. In mature DCs, DC-STAMP is involved in the translocation of 
LUMAN to the Golgi and thereby enables its activation in a process called 
regulated intramembrane proteolysis (RIP).  
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Comparative promoter analysis was used to identify transcription factor binding 
sites (TFBSs) conserved in order and distance, referred to as a promoter 
“framework”. In the first step, 1500bp (-1400/+100bp referring to the 
transcriptional start site) of the mouse and human CD11c promoters and 2000bp (-
1900/+100bp) of the mouse DC-STAMP promoter were compared using the 
analysis tool FrameWorker (Genomatix GmbH).  
 
 
 
Figure 15 CD11c and DC-STAMP share a common promoter framework.  
(a) Identification of a regulatory framework by computational comparison of the CD11c promoter 
with the DC-STAMP promoter across species. TSS, transcription start site. (b) Detailed 
representation of the CD11c/DC-STAMP promoter framework, which contains four elements over 
a length of 250bp. The transcription factor families and their respective orientation on the + and – 
strand are displayed. The indicated distance ranges result from the refinement of the framework in 
the rat CD11c promoter. STAT (signal transducer and activator of transcription), HOMF 
(Homeodomain transcription factors), BRNF (Brn POU domain factors).  
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As a result, two similar frameworks comprising four TFBSs were identified. The 
two frameworks differed only on position three and the remaining elements were 
identical. In the next step, we screened the orthologous promoters in the rat. As 
only one of the two frameworks was partly found in the rat DC-STAMP promoter 
(Fig. 15), we decided to focus on this framework, shown in Figure 15a, for 
verification studies (alternative framework see Fig. 25, APPENDIX). 
The framework comprises 250bp and contains four TFBSs for the following 
transcription factor families: STAT (signal transducer and activator of 
transcription) binds the + strand, whereas HOMF (Homeodomain transcription 
factors) and two members of the BRNF (Brn POU domain factors) family bind the 
– strand (Fig. 15b). 
Importantly, the regulatory region identified corresponds to one of the few 
regions conserved between mouse and human CD11c (data not shown, DiAlignTF, 
Genomatix) and comprises those nucleotides, which have been proposed to be a 
transcriptional enhancer in the human CD11c promoter (95). In addition, the 
fragment of the mouse DC-STAMP promoter (-1565/+131bp) that we previously 
used to drive gene expression specifically in DCs (Fig. 5 and (76)) also contains the 
transcriptional framework described. 
 
5.3.2 Method for in vivo promoter analysis 
In order to experimentally validate this hypothetical promoter framework we 
decided to analyze whether this region plays a role in the transcriptional activity 
of the mouse CD11c promoter. In contrast to the usual approach for promoter 
analysis, which applies cell lines as an artificial system, we decided to analyze the 
promoter in a more physiological setting and tested it directly in vivo. To this end, 
we cloned different fragments of the CD11c promoter (pCD11c) region into self-
inactivating lentivirus upstream of GFP as a reporter gene (Fig. 16a). The resulting 
viruses were used to genetically modify HSCs of C57BL/6 mice, which were 
subsequently injected into irradiated recipient mice. In these chimeras, promoter 
activity was examined in various organs and primary cell types upon 
reconstitution of the hematopoietic system. This method offers an important 
advantage: promoter activity can be measured in steady state cells, as they are not 
manipulated directly- a problematic issue, if working with DCs. 
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In a first attempt to generate a smaller but still functional promoter fragment, we 
examined the activity of a pCD11c1500bp fragment. Different lymphoid organs were 
analyzed by flow cytometry for transgene expression. GFP expression was 
detected preferentially in DC populations from the spleen, thymus and lymph 
nodes (Fig. 16b).  
 
 
 
Figure 16 The pCD11c1500bp drives expression selectively in DCs.  
(a) Schematic representation of the lentiviral-based SIN-vector containing a fragment of the mouse 
CD11c promoter to control expression of eGFP (enhanced Green Fluorescent Protein). CMV, 
cytomegalovirus; Ψ, packaging signal; LTR, long terminal repeat; WPRE, woodchuck hepatitis 
virus post-transcriptional regulatory element; ΔU3, deletion in the U3 region. (b) Analysis of the 
CD11c1500bp promoter activity in different organs. HSCs from C57BL/6 mice were modified by 
transduction with a lentiviral vector presented in (a) and injected into lethally irradiated C57BL/6 
recipient mice. After 8 weeks, single cell suspensions of spleen, thymus and lymph nodes 
(mandibular, axillary and subiliac) from these chimeras were stained for CD11c and MHC-II and 
GFP expression was analyzed by flow cytometry. For detailed quantification, we gated on CD11chi 
and CD11clo cells and histograms were displayed. The data shown are representative of two 
independently performed experiments with 4-5 mice per group. 
 
Low viral titers (MOI between 0.2 and 0.5) were used for transduction of HSCs in 
order to avoid multiple insertions per cell. This explains the occurrence of CD11c 
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positive, but GFP negative cells. The levels of GFP corresponded to the expression 
of CD11c, as CD11clo cells also showed less GFP expression than CD11chi cells 
(21.6% compared to 53.9% in spleen, respectively). This suggests that the artificial 
CD11c promoter fragment used contains important regulatory regions allowing 
similar expression like the CD11c promoter in its normal genomic context.  
 
5.3.3 Sequential deletion analysis of the mouse CD11c 
promoter and evaluation in vivo 
To further characterize the CD11c promoter region and verify the CD11c/DC-
STAMP promoter model, the 5’ end of the promoter was sequentially truncated 
and the resulting constructs (Fig. 17a) were analyzed in detail for their potential to 
drive gene expression in various cell types of the immune system (for gating 
strategy see Fig. 26, APPENDIX). Two different analysis methods were used: 
histogram overlays illustrate the results in the best way, but lack the possibility of 
statistical analysis (Fig. 17b). As an alternative, the mean values of percentage and 
intensity of gene expression were determined (Fig. 18).   
 
The CD11c promoter constructs between 2000 and 750bp were found to be 
comparable in their gene expression profiles: GFP expression could be observed in 
all DC populations. The CD8 positive DC subset produced the highest levels of the 
transgene in comparison to CD8 negative DCs or plasmacytoid DCs (pDCs). The 
latter were lowest for GFP, but this is in accordance with their intermediate 
expression of CD11c. In contrast, all other cell types tested expressed only 
negligible amounts of GFP. In T and B cells expression was absent and very low 
promoter activity was detected in monocytes, neutrophils and NK cells (Fig. 18).  
 
Strikingly, expression in conventional DCs was lost completely in the pCD11c400bp 
fragment, whereas some residual activity in pDCs remained. These data identify a 
region of 350bp, located between 750 and 400bp and containing the CD11c/DC-
STAMP-model, as core promoter region driving CD11c gene transcription. The 
fact that gene expression is abrogated without the described region experimentally 
validates the importance of the CD11c/DC-STAMP-model, which had been found 
by computational analysis.  
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Figure 17 Sequential deletion analysis of the CD11c promoter in vivo.  
(a) Schematic illustration of pCD11c deletion constructs with the respective localization of the 
CD11c/DC-STAMP promoter model. (b) Promoter activity of different sizes of the mouse CD11c 
promoter measured by flow cytometry. Spleen cells from bone-marrow chimeras generated with 
HSCs transduced with lentiviral constructs carrying the indicated pCD11c-segment were analyzed 
for GFP expression. The different cell types were identified based on the expression of the 
indicated markers. Overlays were generated after gating on the relevant population using cells 
from C57BL/6 mice as negative controls. For every promoter construct, the data shown are 
representative of two independently performed experiments with 4-5 mice per group.  
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Figure 18 Statistical analysis of in vivo promoter activity.  
Various cell types from bone marrow chimeras generated with different fragments of the mouse 
CD11c promoter driving GFP expression were analyzed. Percentage and level (MFI) of GFP 
expression are displayed. The MFI (mean fluorescence intensity) represents the whole respective 
cell population and is calculated as MFICD11c-GFP - MFIC57BL/6. The representative overlay data shown 
in Figure 17 are statistically analyzed with all animals per group (n=6 for CD11c2000bp and n=5 for 
CD11c400-1500bp). Error bars represent standard deviations (SD). For each promoter construct, 
experiments were repeated independently 2-3 times. 
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5.3.4 Segmental analysis of the CD11c/DC-STAMP 
promoter model 
To further prove the transcriptional potential of the CD11c/DC-STAMP-model we 
next tested whether the relevant region is still capable of driving DC-specific 
expression, when taken out of its original genomic context. Therefore the 
pCD11c750-400bp region was cloned into a lentiviral backbone upstream of the 
minimal SV40 promoter and GFP as a reporter gene (Fig. 19a).  
 
 
 
Figure 19 Segmental analysis of the CD11c/DC-STAMP promoter model.  
(a) Schematic illustration of the different parts of the CD11c/DC-STAMP promoter model and 
their respective location. pCD11c750-400bp, pCD11c750-574bp and pCD11c500-400bp were cloned upstream of 
a SV40 minimal promoter into a lentiviral vector. (b) In vivo promoter analysis of the three pCD11c 
fragments indicated and the minimal SV40 promoter alone. Spleen cells from bone-marrow 
chimeras were analyzed for GFP expression by flow cytometry. Shown are histogram overlays of 
cells from C57BL/6 mice as negative controls. Data shown are representative of three 
independently performed experiments (n=4-5). 
 
For the minimal SV40 promoter alone, no in vivo activity was detected, but the 
presence of the pCD11c750-400bp region resulted in GFP expression preferentially in 
DCs (Fig. 19b), which was comparable to the longer CD11c promoter fragments 
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(750-2000bp). The fact that this 350bp region can also act isolated in the context of 
a minimal promoter identifies the sequence as a DC-specific enhancer. 
To dissect the roles of the four TFBSs in the CD11c/DC-STAMP model, we 
investigated the two halves containing two TFBS elements each, again employing 
the minimal SV40 promoter (Fig. 19a). The first part (pCD11c750-574bp) was capable 
of inducing some expression in DCs, but not to the same extent as the full region 
(Fig. 19b). In contrast, the second part (pCD11c500-400bp) could not drive any 
expression in conventional DCs, but did lead to expression in pDCs and other cell 
types like NK cells and B cells. This shows that the second half of the CD11c 
enhancer with the putative two binding sites for the transcription factors of the 
Brn POU family does not play a major role in gene transcription in DCs, whereas 
the region containing the binding sites for the STAT family and the Homeodomain 
transcription factors is of significant importance. Notably, the best promoter 
activity was achieved when the whole 350bp region was used and all four 
elements could work together. 
 
5.3.5 Identification of coregulated genes using a 
combinatorial approach 
The characterization of the CD11c/DC-STAMP model consisting of TFBSs in a 
defined orientation can be used to search for novel genes, which have the same 
organization of regulatory elements within their promoters and have not been 
linked to DC biology before. To this end, a database of 72.900 mouse promoters 
was screened (ModelInspector, Genomatix). Of those, only 49 promoter sequences 
(0.07% of all sequences, Table 4, APPENDIX) were found to contain the 
CD11c/DC-STAMP model. To create an additional line of evidence, we employed 
another platform, the “immunological genome project” (www.immgen.org) (80). 
In this approach, gene expression data of various cell types across the immune 
system are compared and gene correlation is calculated by principal component 
analysis. Using this database two genes from the promoter search were linked to 
CD11c: Pftk1 and Ppef2. According to the “immunological genome project” Pftk1 
is correlated to CD11c, while Ppef2 shows correlation to Pftk1 (Fig. 20). 
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Figure 20 Gene constellation analysis based on gene expression profiles.  
Immgen software was used to find the best 35 genes correlated with CD11c. As Pftk1 was found in 
parallel in the mouse promoter database search, its gene constellation was analyzed subsequently 
and led to the identification of Ppef2.  
 
The promoter sequences of the two genes were screened across species to define 
evolutionary conservation and the precise location of the CD11c/DC-STAMP 
promoter model. Regarding the Pftk1 promoter, the CD11c/DC-STAMP-model 
was partly conserved across species (Fig. 21a): three of four elements were still 
present in the rat promoter and in the human orthologue these two elements, 
which were considered to be of higher importance for CD11c promoter activity 
(Fig. 19), were found. Remarkably, the CD11c/DC-STAMP-model is rotated by 
180° in the Ppef2 promoter (Fig. 21b), but this should not influence the activity, as 
promoters are three-dimensional structures.  
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Figure 21 Identification of Ppef2 and Pftk1 as novel candidate genes.  
The ModelInspector program (Genomatix) was used to scan DNA sequences for the CD11c/DC-
STAMP model. In the first place a database of mouse promoters of annotated genes was screened. 
Then orthologous promoters, which were identified using a comparative genomics tool (ElDorado, 
Genomatix), where analyzed by the same method. Location of the CD11c/DC-STAMP-promoter 
model in Pftk1 promoters across species (a) and in the mouse Ppef2 promoter (b). In the Ppef2 
promoter, the two BRNF binding sites are so close together (10bp) that they appear as one. 
 
To confirm the expression of the two genes in DCs, mRNA isolated from sorted 
primary cells was analyzed by real-time PCR. Both Pftk1 and Ppef2 were 
expressed in DCs, particularly in the CD8 positive subset, but not in CD8 T cells 
from spleen (Fig. 22a). However, as coexpression of genes can occur by unrelated 
events, this result was not sufficient to support the idea of a similar transcriptional 
mechanism. We therefore investigated coregulation of these genes by analyzing 
samples at different time points during in vitro DC generation from bone marrow 
precursor cells, in which the percentage of DCs increases with duration of the GM-
CSF culture. Accordingly, the expression of CD11c and DC-STAMP increased with 
time (Fig. 22b and (87)). In addition, DCs were matured by LPS-stimulation, a 
major hallmark of DC-biology, which resulted in down regulation of both CD11c 
and DC-STAMP (Fig. 22b and (87)). Ppef2 showed a parallel gene expression 
pattern, whereas Pftk1 was already expressed in bone marrow cells and stayed 
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constant during the culture (Fig. 22b). However, Pftk1 mRNA levels decreased 
similarly with DC stimulation. 
 
 
 
Figure 22 Expression of Ppef2 and Pftk1 in DCs.  
(a) Gene expression profiling of ex vivo spleen cells. After density enrichment, DCs were sorted on 
a BD FACSAria instrument based on their expression of CD11c, MHC-II and CD8. CD8 T cells 
were identified as CD3+, CD8+ and CD4- cells. Gene expression levels were calculated relative to 
Ubiquitin C. Error bars correspond to standard deviations between two independently performed 
experiments. (b) Gene expression profiling of DCs generated in vitro. Real-time PCR analysis of 
RNA from samples isolated at day 0, 4, 7 and 8 during DC culture. At day 7 parts of the cultures 
were stimulated over night with LPS (2µg/ml). Shown is relative gene expression after 
normalization to Ubiquitin C. Data are representative of two independently performed 
experiments. Nd, not detectable. 
 
In summary, common promoter frameworks between CD11c and DC-STAMP 
promoters were found using comparative analysis and confirmed by in vivo 
promoter analysis, identifying a DC-specific enhancer region. The information 
about promoter organization (Genomatix) was combined with gene expression 
data (Immgen) and lead to the identification of two candidate genes with potential 
roles in DC biology: Ppef2 and Pftk1. 
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6 DISCUSSION 
6.1 Tolerance induction 
We have demonstrated that expression of a model antigen specifically in DCs 
mediates both central and peripheral tolerance. However, we frequently observed 
that central tolerance was not as effectively induced as peripheral tolerance (Fig. 
10b). Differences in transgene expression between thymic and splenic DCs could 
be one possible explanation for this observation. In DC-STAMP-GFP chimeras (76) 
there was a lower percentage of GFP positive DCs in the thymus compared to the 
spleen. However, analysis of fluorescent intensities did not indicate significant 
differences between these populations. This suggests that transgene expression 
levels might not be the cause of the discrepancy in tolerance induction, but rather 
the distinct developmental origins of the thymic DC compartment. One subset 
(CD8+, SIRPα-), comprising 50% of all thymic DCs, is derived from an early 
intrathymic precursor, whereas pDCs and the CD8- SIRPα+ DC subset arise from 
an extrathymic precursor that homes partially differentiated to the thymus (96). In 
parabiosis experiments (97) it was not possible to replace this thymus-resident 
precursor and it is unclear whether the irradiation protocol used in our setting 
depletes it. The fact that the percentage of GFP positive DCs was reduced in the 
thymus argues for there being difficulties in replacing the early intrathymic 
precursor and the resulting DC subset, similar to other radio-resistant DC-subsets 
such as Langerhans cells of the skin (98). In thymic DC stainings we did not 
distinguish between resident and migratory populations and can therefore not 
ultimately answer this question. 
Concerning the DC-STAMP-OVA model, it cannot be assumed that all thymic 
DCs must express antigen to induce central tolerance under normal conditions. 
However, as we used TCR transgenic T cells present in artificially high 
frequencies, antigen expression on many DCs could still be necessary to ensure 
optimal deletion. 
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6.2 Peripheral T cells in the thymus 
In accordance with previous findings (59, 60, 62) we showed that mature OT-I T 
cells isolated from lymph nodes are able to home back to the thymus in irradiated 
hosts. These cells were found already at day 5 after transfer as well as at later time 
points (8 weeks). Our results did not distinguish whether the T cells, once in the 
thymus, persist there or if it is a circulating movement, in which they come and 
go. Thymic re-entry of OT-I T cells was possible both in the presence (Fig. 7,9,13) 
or absence of their cognate antigen (Fig. 8). However, re-entry seemed to be more 
efficient when antigen was present: In the OT-I BMàRIPmOVA experiment (Fig. 
7), about 60 000 mature OT-I T cells that naturally occur in the BM were 
transferred. As this number of mature CD8 T cells occurs under physiological 
circumstances in the BM, it served as a basis for all following experiments.  
In contrast, in the OT-IàB6 experiment (Fig. 8) much more (6.5x106) OT-I T cells 
were injected together with syngenic BM. In RIPmOVA hosts, 1x105 OT-I T cells 
were detected in the thymus at day 8 after transfer, whereas in B6 hosts - even 
though more cells were transferred - only 1x104 cells were found to have re-
entered at day 11. These findings clearly indicate that OT-I T cells favor thymic re-
entry in the presence of antigen. In line with this, it has previously been observed 
that allogenic compared to syngenic T cells preferentially home to the thymus (99). 
 
The phenomenon that mature T cells re-enter the thymus has been described 
before and various functions for these cells were proposed (61), e.g. induction of 
positive selection (64), maintenance of mTECs (100) or induction of negative 
selection to antigens they passively acquire through their TCRs (68, 101).  
As we have developed a model to induce central tolerance by transcriptional 
targeting of OVA as a model antigen to DCs (76), we decided to address the 
question whether re-entering T cells would interfere with negative selection in the 
thymus. We were able to show that the presence of mature re-entered OT-I T cells 
in the thymus indeed prevented negative selection of both TCR transgenic CD8+ 
and CD4+ T cells (OT-I and OT-II) and polyclonal CD8 T cells with OVA 
specificity. This was due to Ag-specific eradication of DCs and mTECs by re-
entered mature OT-I T cells. However, this observation is restricted to OT-I T cells, 
which express a transgenic TCR with a defined affinity. It will be interesting to 
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investigate whether CD8 T cells with different specificities are also able to delete 
APCs in the thymus. 
 
We demonstrated that mTECs can also be targets of re-entering CD8 T cells in the 
ΔCD8 OT-I BMàRIPmOVA model (Fig. 13), in which the BM was either spiked 
with mature OT-I T cells or not. In this system, OVA expression is controlled by 
the insulin promoter and can therefore be considered as a tissue restricted antigen 
(TRA), which is expressed by mTECs. In the presence of mature re-entered OT-I T 
cells significantly more endogenous OT-I T cells developed in the thymus, which 
indicates less central deletion and indirectly shows the removal of OVA 
expressing mTECs. To provide more direct evidence for Ag-specific deletion of 
mTECs, it would be necessary to compare mTECs from the two groups by qPCR 
analysis of OVA mRNA. mTECs are a rare cell type, which makes isolation of 
sufficient material for analysis very difficult. The fact that each TRA is only 
expressed by a minor subset of mTECs (102) further complicates this approach. 
In our setting, thymic cell numbers were diminished by the irradiation procedure 
and were further compromised under diabetic conditions. Therefore it was not 
possible to isolate sufficient amounts of mTECs with high purity from these mice. 
Nevertheless, when T cells developed in a RIPmOVA thymus in the absence of 
mature peripheral OT-I T cells, which allowed normal encounter of OVA 
expressed by mTECs, their surface marker expression was significantly different 
(Fig. 13d): half of the T cells displayed strongly reduced levels of Thy1.1. This 
surface molecule is widely used as a standard T cell marker, but has also been 
implicated to function in fine-tuning T cell activation (103). Two reports (84, 85) 
provide evidence that Thy-1 is downregulated in response to antigen. This, 
together with the observed CD69 upregulation (Fig. 13d), suggests that the 
developing T cells indeed recognized OVA in the thymus. In contrast, the 
presence of mature OT-I T cells in the thymus prevented Thy-1 downregulation 
and reduced CD69 upregulation on developing T cells, indicating the removal of 
OVA-expressing mTECs. 
 
Our data demonstrate that thymus re-entry of mature CD8 T cells can lead to Ag-
specific removal of mTECs and DCs with concomitant loss of central tolerance and 
the resulting appearance of self-reactive peripheral T cells. 
 
80 
Of course, it was also of interest to ascertain whether the self-reactive CD8 T cells 
are able to exert effector functions. Those OT-I T cells, which could escape thymic 
deletion in DC-STAMP-OVA chimeras due to the presence of mature OT-I T cells, 
had a surface phenotype similar to naive OT-I T cells in the spleen (Fig. 11c). But 
there were still some OVA expressing DCs left in the spleen (Fig. 11d), which 
could exert a tolerogenic effect on those escaped OT-I T cells. However, lentiviral 
modification generates an artificially high frequency of OVA-expressing DCs and 
under normal conditions they would probably be completely removed. Further 
experiments showed that the escaped OT-I T cells can indeed be restimulated to 
produce cytokines like IFN-γ (Fig. 14d), which suggests that they could function as 
effector cells. 
Also in the OT-IàRIPmOVA mice it was difficult to address the question of cell 
functionality. There was a higher frequency of endogenous OT-I T cells in the 
thymus, if mature OT-I T cells acted to remove OVA-expressing mTECs (Fig. 13). 
However, simultaneously with endogenous OT-I T cells leaving the thymus, the 
adoptively transferred OT-I T cells had already destroyed the pancreas. As such, 
the self-reactive potential of those OT-I T cells, which escaped thymic deletion, 
could not be investigated. Other experimental approaches are needed to clarify 
this issue.  
 
Given that thymus escaping self-reactive T cells would indeed be functional, this 
result has important implications for bone marrow transplantation settings. In 
allogeneic bone marrow transplantation, donor T cells can broadly damage the 
host thymus (thymic GVHD). This can be mediated by secretion of IFNγ (104) or 
by mechanisms involving FasL and TRAIL (99). This overall destruction of the 
thymic epithelium impairs T cell development from transplant BM, which is 
essential for long-term immunity and survival of the patients. But there is not only 
a failure to reconstitute the T cell compartment, the damage can even lead to the 
loss of negative selection and appearance of T cells with anti-host reactivity (105). 
Our findings suggest that, in addition to overall thymic destruction, adoptively 
transferred T cells can eliminate antigen-presenting cells (DCs or mTECs) in a 
selective and Ag-specific manner. The elimination of APCs presenting self-Ag 
allows an increase in the generation of self-reactive T cells. As a consequence, 
endogenous self-reactive T cells might contribute to the continuation of GVHD 
and autoimmunity after BM-transplantation.  
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It is also possible that thymus re-entering T cells could play beneficial roles in 
therapy such as the highly successful adoptive transfer of tumor-specific T cells in 
immune depleted cancer patients (106). Here, the removal of tumor- (self-) Ag 
presenting thymic DCs and mTECs (102, 107) might positively enhance the 
endogenous anti-tumor repertoire of the patients. However, as single mTECs 
express many other self-Ags besides those recognized by tumor-specific T cells, 
mTEC eradication could lead to a collateral loss of self-tolerance. It will be 
interesting to investigate the potential relevance of our findings to adoptive 
therapy treatments in clinical settings. 
 
6.3 In vivo promoter analysis 
It has been previously shown in transgenic mice that a 5.5kb-fragment upstream 
of the transcriptional start site of the mouse CD11c gene targets transgene 
expression to DCs (86). Although this approach was successfully adopted by 
many different labs (108-112), and the human CD11c promoter has been studied 
extensively (reviewed in (113)), there has to date been no information about the 
location of regulatory elements in the mouse orthologue.  
 
The comparison of CD11c and DC-STAMP promoters by a computational 
approach identified a promoter model and drew attention to a shared 250bp 
region. By in vivo promoter analysis using lentiviral vectors (Fig. 16), we 
confirmed that this particular region in the CD11c promoter is important to drive 
DC-specific expression (Fig. 17). Recent findings of Ni et al. (114) support our 
results, as they successfully used a 700bp fragment of the CD11c promoter in a 
vaccination approach against tumor antigens. The promoter model we described 
here is still present within this 700bp region. The fact that gene expression driven 
by pCD11c constructs between 2000 and 750bp results in similar expression 
profiles (Fig. 17) argues against other positive or negative regulatory elements 
within this region.  
 
Some cell types, such as pDCs, monocytes, macrophages and NK cells display low 
expression of CD11c. Likewise, we observed only low-level promoter activity in 
monocytes and splenic macrophages (Fig. 18 and data not shown). In NK cells, the 
CD11c promoter also drove only weak transgene expression in our experiments 
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(Fig. 18). This is in accordance with previous findings in transgenic mice using the 
5.5kb promoter (111). However, it has been demonstrated that this low expression 
level can still be sufficient to change the NK cell phenotype (115). In contrast, 
pDCs display intermediate expression levels, but are nevertheless resistant to 
diphteria toxin, if the corresponding receptor is expressed under the control of the 
CD11c promoter (116). These findings emphasize that the type of application and 
transgene have a strong impact on the outcome of CD11c-driven gene expression. 
 
We investigated both CD11c and DC-STAMP by in vivo promoter analysis (Fig. 5 
and 17). A comparison of the tissue specificity of the two promoters revealed an 
interesting difference: the 1.7kb DC-STAMP promoter fragment displayed only 
minor activity in pDCs. Most publications regarding DC-STAMP do not 
distinguish between cDCs and pDCs in their experiments. Therefore it is unclear 
whether our findings correspond to the mouse DC-STAMP promoter in its 
genomic context and DC-STAMP is indeed not expressed in pDCs. Alternatively, 
the missing gene expression in pDCs could be attributed to the reduced promoter 
length used in our experiments. If this is the case, it would mean that regulatory 
elements driving gene expression in pDCs are located outside the 1.7kb region we 
tested. In relation to the DC-STAMP-OVA model, this suggests that although 
pDCs are able to induce tolerance (117), they are dispensable for this process in 
our setting.  
Both CD11c and DC-STAMP promoters were found to drive gene expression with 
a similar intermediate strength, although the CD11c promoter displayed a slight 
tendency to have superior activity. However, DC-STAMP mRNA levels are so 
much lower, close to the detection limit in quantitative PCR and microarray assays 
that a major difference in gene expression levels would be expected. These 
findings imply differences in post-transcriptional regulation of CD11c and DC-
STAMP mRNA that influence their stability. 
 
Most of the existing knowledge on transcription factors that are related to DC 
biology concerns the development of the various DC subsets from hematopoietic 
stem cells. Using transcription factor knockout mice both positive and negative 
effects on DC development have been described (Fig. 23). Only recently the 
transcription factor E2-2 has been defined as a molecular switch between pDC and 
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cDC development (118): in its absence pDCs develop into cDC-like cells, thus E2-2 
negatively regulates the default cDC pathway (Fig. 23). 
 
 
 
Figure 23 Transcription factors in DC development. 
Different transcription factors are necessary for the development of conventional DC, Langerhans 
cells (LC) and plasmacytoid DC (pDC) from HSCs. Activating and inhibitory transcriptional 
activity is illustrated in green and red, respectively. LT, long-term; ST, short-term. Modified from 
(119). 
 
From the TF families comprised in the CD11c/DC-STAMP promoter model in this 
study, none of the members has previously been linked to DC biology or found to 
be preferentially expressed in DCs. The HOMF (homeodomain transcription 
factors) and BRNF (Brn Pou domain factors) families display a very wide tissue 
distribution and only the STAT (signal transducer and activator of transcription) 
family shows a more restricted activity, namely in breast and hematopoietic cells 
(MatBase, Genomatix). However, considering the variety of promoter sequences 
within the genome and the limited number of transcription factors, it is likely that 
transcriptional regulation is a concerted action that is dependent on the 
combination and availability of particular factors.  
An interesting characteristic of the BRNF family is the tendency to homodimerize 
(120). This is also likely to occur in the CD11c/DC-STAMP promoter model, as 
two members of this family bind in close proximity (Fig. 15b).  
Our results assigned a prominent role to a STAT family member in the regulation 
of CD11c, as deletion of this particular binding sequence resulted in loss of DC-
specific expression (Fig. 19). This finding is supported by the fact that interleukin 
E2-2 
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(IL)-4, which signals via STAT6 (121) and is added in some culture conditions to 
generate DCs, does indeed enhance the expression of DC-STAMP and CD11c (87, 
122). 
 
After refinement of the CD11c/DC-STAMP promoter model, it was used to screen 
a mouse promoter database, which revealed 49 genes predicted to contain the 
CD11c/DC-STAMP model in their promoter regions (Table 4, APPENDIX). We 
combined this result with information about gene expression, which is used to 
calculate so called gene constellations (Immgen). The two candidate genes Pftk1 
and Ppef2 were found together with CD11c in both approaches (Fig. 24). DC-
STAMP could not be included in gene expression analysis, as mRNA levels are too 
low for detection in microarray asays.  
 
 
 
Figure 24 Combinatorial approach for promoter analysis. 
The combination of two computational tools led to the identification of three common genes: 
CD11c, Pftk1 and Ppef2. Searching a mouse promoter database with the CD11c/DC-STAMP model 
resulted in 49 genes. Analyzing gene constellations based on expression profiles resulted in 70 
correlated genes (35 with CD11c, 35 with Pftk1). DC-STAMP could not be included, as expression 
levels are too low for detection in microarray analysis. 
 
We assume that Pftk1 and Ppef2 could have functional and so far undiscovered 
roles in DC biology. In the mouse, Pftk1 is highly expressed in brain and testis, but 
its function is unclear. It is also known as Cyclin-dependent Kinase (Cdk)-14 and 
for human Pftk1 a role in cell cycle progression and cell proliferation has been 
demonstrated (123). In addition, Pftk1 interacts with Cyclin D3 (123) and Cyclin Y, 
a novel membrane-associated cyclin (124). This function seems to not be rather 
necessary for DCs, as they were originally considered to be an end-stage, non-
dividing cell type. However, there is now evidence that DCs undergo at least a 
limited number of divisions in spleen and lymph nodes (125, 126). Moreover, CD8 
positive DCs, which have higher levels of Pftk1 mRNA, also have a faster turnover 
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compared to other DC subsets. Furthermore, Pftk1 is also expressed in post-
mitotic cells (127), which suggests additional functions beyond the cell cycle. Pftk1 
expression does not follow the same kinetics like CD11c and DC-STAMP (Fig. 
22b), as it is already present in bone marrow cells, as suggested by public 
microarray data (GEO profiles, NCBI). Therefore it is most likely that other 
regulatory elements might be active in the Pftk1 promoter in addition to the 
CD11c/DC-STAMP promoter model. It is of interest to note that one member of 
the BRNF family, namely Brn3a, has already been described to be important for 
transcriptional regulation of the Pftk1 gene, although in a different tissue (128). 
 
Ppef2 is a serine/threonine-protein phosphatase with two EF-hand calcium 
binding domains at the C-terminus that interacts with calmodulin via its N-
terminus (129), thereby providing a dual regulation mechanism by calcium. 
Recently, it has been shown that Ppef2 binds and negatively regulates ASK-1 
(apoptosis signal regulating kinase) (130), which is activated by oxidative stress 
and can transduce apoptotic or inflammatory signals (131). The fact that DCs are 
10 times more resistant to reactive oxygen species (ROS) than T lymphocytes (132) 
could be explained by the presence of Ppef2. Another possible role of Ppef2 in DCs 
could be in the control of cytokine production, as ASK-1 is required for the IL-6 
production in response to LPS (133). We have shown that Ppef2 is downregulated 
after LPS stimulation (Fig. 22b), potentially clearing the way for effective cytokine 
production in the mature DC. It will be interesting to assess how these newly 
identified genes are in fact functionally linked to DCs in future studies. 
Interestingly, all of the pCD11c constructs between 750 and 2000bp showed higher 
gene expression in CD8 positive DCs than in other subsets (Fig. 17 and 18). This is 
consistent with results in transgenic mice using the 5.5kb promoter (112). Even 
when the enhancer region alone was used together with the SV40 minimal 
promoter, this characteristic persisted (Fig. 19). In addition, the same trend was 
observed for DC-STAMP (76) and the newly identified genes, Pftk1 and Ppef2, at 
least regarding mRNA levels (Figure 22a and GEO profiles, NCBI). This argues for 
the idea that the enhancer region we described is not only specific for DCs, but 
also shows a higher activity in CD8 positive DCs. As this subset is important for 
cross-presentation (134, 135) and thereby for the generation of optimal cytotoxic 
immune responses, this feature makes the enhancer an attractive tool for 
engineering of vaccination vectors. 
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Common promoter frameworks between the CD11c and DC-STAMP promoters 
were found using comparative analysis and confirmed by in vivo promoter 
analysis, identifying a DC-specific enhancer region. This information was 
subsequently used to detect genes previously not associated with DC biology. As 
such, a transcriptional network could be defined that orchestrates the expression 
of coregulated genes in DCs. The power of this combinatorial approach will help 
to face the challenge of dissecting complex transcriptional networks.   
 
6.4 Conclusion 
The lentiviral gene transfer system developed in this study offers multiple 
interesting applications, as stable gene expression is achieved without the need to 
produce transgenic mice. The generation of bone marrow chimeras with 
lentivirally transduced HSCs is substantially less time consuming than making 
novel transgenic mice. As such, important biological questions can be addressed 
in a relatively short period of time in vivo. 
DC-specific gene expression by transcriptional targeting using the mouse CD11c 
or DC-STAMP promoters can be used to further investigate aspects of DC biology. 
These results could help to develop novel protocols for immunomodulation, 
which potentially contribute to improving vaccination, autoimmunity and 
transplantation treatments in the long run.  
A second application of the lentiviral gene transfer system is the novel method of 
in vivo promoter analysis. In the field of promoter analysis, most approaches are 
conducted in vitro and involve cell lines, as primary cells are difficult to 
manipulate for gene transfer. This artificial setting can only give a first indication 
of promoter function, but cannot reflect the physiological situation.  
In our in vivo system, promoter analysis is performed with primary cells that have 
developed from lentivirally infected HSCs. The analyzed cells are derived from a 
natural environment and have not been directly manipulated. Furthermore, 
promoter activity can be compared in one cell type in different organs, e.g. DCs in 
the spleen, lymph nodes and thymus. 
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7 APPENDIX 
 
 
 
Figure 25 Alternative framework in the CD11c and DC-STAMP promoters.  
In comparison to the model presented in Fig. 15, the only difference is evident on position three: a 
CART binding site replaces the first of the two BRNF binding sites. (a) The location of the 
alternative CD11c/DC-STAMP framework in CD11c promoters and DC-STAMP promoters across 
species is displayed. TSS, transcription start site. (b) Detailed representation of the alternative 
CD11c/DC-STAMP promoter framework, which contains four elements over a length of 250bp. 
The transcription factor families and their respective orientation on the + and – strand are 
displayed. The indicated distance ranges result from the refinement of the framework in the rat 
CD11c promoter. STAT (signal transducer and activator of transcription), HOMF (Homeodomain 
transcription factors), CART (cartilage homeoprotein-1), BRNF (Brn POU domain factors).  
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Figure 26 Gating strategy for in vivo promoter analysis.  
Splenocytes were stained with different combinations of antibodies and the different cell types 
were identified by the progressive gating strategy shown from left to right. Representative blots of 
a C57BL/6 mouse are displayed. If possible, the FL-3 channel was spared to remove 
autofluorescent cells (middle column of NK cells, monocytes and neutrophils). The neutrophils-
antibody was labeled with biotin and detected by streptavidin-APC.  
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Table 4  List of genes predicted by ModelInspector analysis. 
These genes were found by screening a mouse promoter database and were predicted to contain 
the CD11c/DC-STAMP promoter model in their regulatory region. 
 
Gene Gene ID Name 
Nrk 27206 Nik related kinase 
Braf 109880 Braf transforming gene 
Strn3 94186 Striatin, calmodulin binding protein 3 
Pmch 110312 Pro-melanin-concentrating hormone 
Nck1 17973 Non-catalytic region of tyrosine kinase adaptor protein 1 
Mecom 14013 MDS1 and EVI1 complex locus 
Dsc1 13505 Desmocollin 1 
Syt4 20983 Synaptotagmin IV 
Ppef2 19023 Protein phosphatase, EF-hand calcium-binding domain 2 
Olfr1098 258842 Olfactory receptor 1098 
Klra2 16633 Killer cell lectin-like receptor, subfamiliy A, member 2 
Inpp4b 234515 Inositol polyphosphate-4-phosphatase, type II 
Ntrk3 18213 Neurotrophic tyrosine kinase, receptor, type 3 
Tchhl1 71325 Trichohyalin-like 1 
Olfr720 258387 Olfactory receptor 720 
Zfp518 72672 Zinc finger protein 518 
Smarcd2 83796 SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily d, member 2 
Fn1 14268 Fibronectin 1 
MII3 231051 Myeloid/lymphoid or mixed-lineage leukemia 3 
Abcb4 18670 ATP-binding cassette, sub-family B (MDR/TAP), member 4 
Metap1 75624 Methionyl aminopeptidase 1 
Brcc3 210766 BRCA1/BRCA2-containing complex, subunit 3 
Olfr1132 258833 Olfactory receptor 1132 
Pde9a 18585 Phosphodiesterase 9A 
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Enpp5 83965 Ectonucleotide pyrophosphatase/phosphodiesterase 5 
Olfr1370 258528 Olfactory receptor 1370 
Pcm1 18536 Pericentriolar material 1 
Stxbp5 78808 Syntaxin binding protein 5 (tomosyn) 
Tnik 665113 TRAF2 and NCK interacting kinase 
Eps15 13858 Epidermal growth factor receptor pathway substrate 15 
Mdn1 100019 Midasin homolog (yeast) 
Phrf1 101471 PHD and ring finger domains 1 
Fryl 72313 Furry homolog-like (Drosophila) 
Gm4190 100043046 Predicted gene 4190 
Gm3114 100041051 Predicted gene 3114 
Bet3l 692132 BET3 like (S.cerevisiae) 
mCG 142697 71783 Ankhd1-eif4ebp3 readthrough transcript 
Dst 13518 Dystonin  
Mll5 69188 Myeloid/lymphoid or mixed-lineage leukemia 5 
Sprr2f 20760 Small proline-rich protein 2F 
Pftk1 18647 PFTAIRE protein kinase 1 
Fam174a 67698 Family with sequence similarity 174, member A 
Pten 19211 Phosphatase and tensin homolog 
Tgfbr1 21812 Transforming growth factor, beta receptor l 
Gm4836 22526 Predicted gene 4836 
Gm5168 382275 Predicted gene 5168 
Tet1 52463 Tet oncogene 1 
Meg3 17263 Maternally expressed 3 
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8 ABBREVIATIONS 
Ag  antigen  
APC  1. antigen presenting cell   
2. allophycocyanin  
AIRE  auto-immune-regulator protein 
Bdnf  brain-derived neurotrophic factor 
BM  bone marrow 
bp  base pair 
CAGE  Cap-analysis gene expression 
CD  cluster of differentiation 
cDNA  complementary DNA  
CFSE  carboxyfluorescein-diacetate-succinimidylester 
CTL  cytotoxic T lymphocyte 
dNTP  desoxyribonucleotidtriphosphate 
DC  dendritic cell 
DC-STAMP dendritic cell-specific transmembrane protein 
DNA  desoxyribonucleic acid 
E. coli  Escherichia coli 
EDTA  ethylenediamintetraacetic acid 
eGFP  enhanced green fluorescent protein 
ER   endoplasmic reticulum 
FACS  fluorescence activated cell sorter 
FBS  fetal bovine serum  
Fc  fragment crystallizable of an antibody 
FITC  fluoresceinisothiocyanate 
for  forward 
5-FU  5-Fluoro-Uracil 
GM-CSF granulocyte-macrophage colony stimulating factor 
GVHD graft versus host disease  
GVL  graft versus leukemia 
h  hour 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HIV  human immunedeficiency virus 
HLA  human leukocyte antigen 
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HSC  hematopoietic stem cell 
HSV  herpes simplex virus 
HSVgB herpes simplex virus glycoprotein B  
IDO   indoleamine 2,3- dioxygenase 
IFN-I  interferon type I (alpha and beta) 
IFN-α/β interferon alpha/beta 
IFN-γ  interferon gamma 
Ig  immunoglobulin 
IL  interleukin 
i.p.   intraperitoneal  
i.v.  intravenous  
kb  kilobase 
LPS  lipopolysaccharide 
LTR  long terminal repeat 
µg  microgram 
µl  microliter 
mRNA messenger RNA 
MFI  mean fluorescent intensity 
MHC  major histocompatibility complex 
min  minute 
MOI  multiplicity of infection  
mTECs medullary thymic epithelial cells 
NK cell natural killer cell 
NKT cell  natural killer T cell 
NLR   nod-like receptor 
OD  optic density 
ORF  open reading frame 
OVA  ovalbumin 
PAMP pathogen associated molecular pattern 
pBS  plasmid Blue Script 
PBS  phosphate buffered saline  
PCR  polymerase chain reaction 
pDC  plasmacytoid dendritic cell 
PD-L1  programmed cell death ligand 1 
PE  phycoerythrin 
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PerCP  peridinin-chlorophyll-a protein 
pfu  plaque forming units 
PRR  pattern recognition receptor 
qPCR  quantitative PCR 
rev  reverse 
RIP  rat insulin promoter 
RNA  ribonucleic acid 
RRE  rev response element 
RT  1. room temperature 
  2. reverse transcription 
SA  streptavidin  
SCF  stem cell factor 
SIN  self-inactivating 
SIINFEKL OVA257-264 
SSIEFARL HSVgB498-505 
SP  single positive (thymocyte) 
STAT  signal transducer and activator of transcription 
Ta  annealing temperature 
TAP  transporter associated with antigen processing 
TCR  T cell receptor 
TFBS  transcription factor binding site 
TH cell  T helper cell 
TGF-β  transforming growth factor beta 
TLR  toll like receptor 
Tm  melting temperature 
TNF-α tumor necrosis factor alpha 
Treg  regulatory T cell  
TRA  tissue-restricted antigen 
TU  transducing units 
UTR  untranslated region 
UV  ultraviolet  
vs.  versus 
v/v  volume per volume 
VSV-G vesicular stomatitis virus glycoprotein G 
WPRE Woodchuck hepatitis virus posttranscriptional regulatory element 
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w/v  weight per volume 
w/w  weight per weight 
XCR1  XC chemokine receptor 1 
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